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Abstract  
Historically, studies of drug biodistribution are traditionally carried out in the later 
stages of pre-clinical pharmaceutical research and development (R&D) using radio-
labelled techniques. Such studies are often slow, expensive and unselective, meaning 
resulting data can be complicated to deconvolute and too late in the development 
pipeline to change the medicine under investigation. 
Mass spectrometry imaging (MSI) has the potential to provide an unlabelled, multiplex 
method of mapping and quantifying molecular distributions within tissues at a much 
earlier stage in the R&D timeline, informing researchers of exposure in target tissue or 
providing evidence of localised and accumulated drug concentration in tissues 
exhibiting symptoms of toxicity. 
The research presented in this thesis begins by exploring the use of MALDI, DESI and 
LESA-MSI in early pharmacokinetic cassette dosing studies. Furthermore, MSI 
techniques were applied to blood brain barrier penetration studies to assess 
compound penetration profiles. Quantitative MSI (qMSI) methods were studied using 
tissue mimetics to generate accurate calibration lines and produce in situ 
concentration data. Finally, region specific qMSI was used to quantify endogenous 
metabolite concentrations and evaluate tumour heterogeneity in several different 
tumour models, identifying a model that would be used in pre-clinical efficacy studies. 
The results indicate that MSI drug distribution studies can be performed much earlier 
in the lead optimisation stage of the drug discovery process. This was done using a 
range of MSI platforms with different sensitivity, spatial resolution and chemical scope. 
The use of LESA-MSI to assess drug blood brain barrier penetration revealed benefits 
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over non-spatially resolved analytical methods. The multiplex nature of MSI analysis 
was shown to mitigate residual blood contamination in brain tissue sections giving 
greater differentiation of poorly BBB permeable drugs. Development of quantitative 
LESA and DESI-MSI methods were used in conjunction with tissue mimetics to show 
that qMSI is a reliable way of generating in-tissue concentration data. qMSI results 
compared favourably with ‘gold standard’ LC-MS approaches. Finally, MALDI-qMSI 
was shown to be capable of generating region-specific concentration data of 
endogenous metabolites in heterogeneous tumour tissues. This culminated in drug 
project selection of a tumour model with a less heterogeneous lactate distribution, less 
intra-tumour lactate variability and a better platform to discriminate lactate modulation 
in drug dosed animals versus control in efficacy studies. 
The research presented in this thesis has shown that the MSI methodology developed 
can be successfully applied to pharmaceutical R&D. The validated protocols can be 
employed earlier in the development timeline allowing researchers time to evaluate 
and react to any data produced. Furthermore, MSI has been shown to be applicable 
in pharmacokinetic, pharmacodynamic and toxicity studies, offering spatially 
enhanced results that complement the data generated using existing analytical 
techniques and hence can make a contribution to safer, more efficacious medicines 
being brought to patients. 
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1. INTRODUCTION 
1.1 Introduction to mass spectrometry imaging and its application in 
pharmaceutical research and development 
During pharmaceutical research and development (R&D) it is essential to have a 
detailed understanding of drug pharmacology, toxicity and distribution. In order to exert 
an effect drug molecules must reach target receptors at the site of action at a 
sufficiently high unbound concentration to deliver efficacy whilst it should not be so 
high that they instigate a toxic response. Plasma concentration measurements have 
traditionally been used as a surrogate for the concentration of drug in tissues but this 
does not always accurately represent the levels within specific organs or sub-
compartments and therefore additional assays are required in the development of an 
understanding of the efficacy or toxicology of a new chemical entity in vivo. Drug 
distribution studies are typically performed in later stages of the development pipeline 
using radio-labelled compounds in techniques such as quantitative Whole Body 
Autoradiography (qWBA)1,2 or by using tissue homogenisation followed by LC-MS3,4. 
Whilst these analytical techniques still have relevance in the progression of a new 
chemical entity, they are often time consuming, costly and misleading due to the non-
specific method of detection being used. Radiolabelled drugs have the potential to 
undergo metabolism, often their primary metabolites can contain the radiolabel and 
this can misrepresent the distribution profile of the drug rendering the data ambiguous. 
In a rapid moving R&D environment it is beneficial to have this drug distribution 
information at an early stage to confirm drug delivery at the active site or to highlight 
drug accumulation in an organ where toxicity may have been encountered. 
Furthermore, it is essential to have an indication of efficacy in target tissues to limit 
attrition further down the R&D process. 
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Mass Spectrometry Imaging (MSI) is a technique that is used to visualise the two-
dimensional (and 3D) molecular distribution of endogenous compounds5, drugs6, 
lipids7, proteins8 and peptides9 in biological tissue. It encompasses a range of mass 
spectrometry based platforms all based on different surface sampling ion sources, 
each variation offering similar but slightly different properties in terms of speed, 
sensitivity, chemical scope and spatial resolution. Essentially, each technique rasters 
or continuously scans across tissue sections acquiring a constant full mass spectrum 
at each pixel or coordinate, each mass peak within the spectrum is assigned an 
arbitrary intensity that can be colour coded into a heat map image describing the 
relative abundance of an analyte within the tissue. 
Matrix Assisted Laser Desorption/Ionisation (MALDI) is arguably the most 
predominant MSI technique used in research. MALDI is a ‘soft’ ionisation technique 
allowing the detection of large, non-volatile and labile molecules by mass 
spectrometry. It was introduced in the early 1980’s10, but the first reported use of 
MALDI for imaging was made in 1984, it did not however gain widespread attention 
until the seminal paper from the Caprioli group in 199711. MALDI uses a pulsed, high 
repetition rate laser beam focused at the required spatial resolution making it ideal for 
microscopic interrogation of chemical entities from tissue sections. MALDI initially 
suffered from poor reproducibility which cast a cloud over its application within the 
imaging field but the technique has been developed significantly over the intervening 
years with changes in instrumentation and improved sample preparation overcoming 
these initial concerns and constituting a reliable, robust and widely applicable MSI 
platform capable of qualitative and quantitative analysis. 
Since its inception MALDI-MSI has been joined by various complementary imaging 
capable ion sources. Desorption Electrospray Ionisation (DESI) is being increasingly 
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employed in various academic and industrial laboratories. As its name suggests, DESI 
is an ambient ionisation technique based on traditional electrospray ionisation12 and 
as such has a wide and varied chemical applicability. Its use was once viewed by 
researchers as being something of a ‘dark art’ but recent years have seen it being 
developed by instrument manufacturers and researchers into a robust analytical 
technique capable of molecular imaging at spatial resolutions of ~50-100 µm13. The 
technique was first reported in 200414 and has grown to become a primary method of 
MSI. DESI has been widely applied to areas such as lipid profiling7, neurotransmitter 
analysis15, metabolic phenotyping of tumours16 and xenobiotic drug distribution 
studies17. NanoDESI18 is a further development of the technique, it is also 
fundamentally related to Liquid Extraction Surface Analysis (LESA) discussed further 
below. NanoDESI has been used in quantitative drug analysis19 as well as a variety of 
other applications20,21. Spatial resolution is higher than DESI at around 12µm22. 
LESA is an MSI technique that has been successfully shown to be applicable in the 
areas of metabolic profiling23, identification of proteins24 and drug imaging6. Like DESI 
it is based upon traditional ESI, giving the technique wide applicability. LESA is 
sometimes referred to as liquid micro-junction surface sampling25 and essentially uses 
a robotic pipette tip to introduce an extraction solvent to predefined areas on a tissue 
section. The extraction liquid is dispensed onto the tissue whilst maintaining a liquid 
junction with the pipette tip, it is then aspirated and sprayed into the mass spectrometer 
usually via a nanoelectrospray chip26. The main drawback of the LESA technique is 
its low spatial resolution, effectively restricted by the diameter of the pipette tip/syringe 
needle (typically 1000µm) being used to transfer the liquid extraction solvent. A 
fundamental benefit of this low spatial resolution is the introduction of high amounts of 
analyte into the mass spectrometer rendering the technique as a high sensitivity 
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alternative to MALDI and DESI which are both limited by inherent limit of detection 
thresholds for different chemical classes. 
Many other MSI platforms have been developed to perform similar analyses, 
secondary ion mass spectrometry27 (SIMS), which pre-dates MALDI as an MSI tool, 
laser ablation electrospray ionisation28 (LAESI) and laser desorption ionisation29 (LDI) 
are but a few that are being used but have yet to find widespread implementation, 
usually due to high costs or limited applicability. There are far too many other 
techniques to discuss in this thesis so this introduction will focus on the primary 
techniques used in this research project. For a full description of all MS imaging 
modalities see the recent review by Paine et al.30. 
An important factor in any MSI platform is the mass analyser that is used in conjunction 
with the ion source. Various different mass analysers are used including time of flight31, 
triple quadrupole32, ion trap33 and ion cyclotron resonance34 instruments. Each offer 
differences in sensitivity, mass resolution, mass accuracy and scan rate and care must 
be taken when choosing which instrument to purchase, tailor making an MSI platform 
to the research being undertaken. 
Sample pre-treatment is another fundamental part any MSI workflow (a typical MSI 
workflow can be seen in figure 1). As mentioned earlier most of the techniques 
employed have benefitted from development of robust sample preparation methods 
including normalisation of the mass spectrometer response by applying internal 
standards to the tissue35, stabilisation of endogenous compounds36,37, tissue 
thickness38 and sample storage39. This has helped MSI gain a good reputation as a 
viable alternative to traditional methods of analysis within industry, with the main 
pharmaceutical companies now establishing MSI groups to facilitate drug discovery.
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1.2 Ionisation mechanisms and interfaces 
1.2.1 Matrix assisted laser desorption ionisation (MALDI) 
The MALDI ionisation interface is described in figure 2a. The ionisation process 
requires the application of large concentrations of an energy absorbent organic 
compound, called the MALDI matrix, which is coated across the surface of the sample 
to be analysed (in the case of MSI a tissue section). The MALDI matrix is applied as 
a solution that promotes extraction of the analytes from the tissue, subsequent 
evaporation of the solvent causes the matrix and analytes to co-crystallise in a spatially 
representative way. A pulsed UV laser beam (usually 337 or 355 nm) is used to strike 
the surface of the matrix in an evacuated chamber. The matrix crystals absorb the 
ultraviolet light and convert it to heat energy, heating rapidly and vaporising, ionisation 
occurs in the resulting vaporisation plume, effectively ablating the sample into the 
mass spectrometer40. In the case of MSI the laser pulse is repeated in a raster pattern 
at spatially distinct intervals across the tissue. 
 
1.2.2 Desorption Electrospray Ionisation (DESI) 
The DESI interface is described in figure 2b. The technique is referred to as an ambient 
ionisation source in contrast to MALDI which is performed under high vacuum. A 
charged nebulising solvent (usually 95% v/v methanol/water) is sprayed from an 
emitter probe directly at the sample surface extracting the analytes and creating 
secondary droplets which dry and release the ions in the gas phase into the mass 
spectrometer. The sample is usually situated on a freely moving sample stage which 
in the case of DESI-MSI moves from one side of the tissue to the other in spatially 
separated rows whilst the mass spectrometer acquires a continuous spectrum. 
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Ionisation occurs via different mechanisms for small and large molecules41. Large 
molecules are ionised by desorption in the liquid phase where multiple charges in the 
droplet can be transferred to the analyte. Smaller molecules undergo charge transfer 
of an electron or proton either between the solvent ions and the analyte on the sample 
surface or between gas phase ions and the analyte on the sample surface or between 
a gas phase ion and the analyte in the gas phase. 
1.2.3 Liquid Extraction Surface Analysis (LESA) 
The LESA interface is described in figure 2c. It is essentially a robotic pipetting system. 
A volume of extraction solvent is aspirated into a conductive pipette tip. The robot 
moves to a predetermined coordinate and dispenses a small volume of the extraction 
solvent onto the sample surface whilst maintaining a liquid junction between the tip 
and the tissue, extraction occurs following the normal principles of solvent extraction. 
After a slight delay the solvent is re-aspirated into the pipette tip and the robot takes it 
to a nano-electrospray chip where it follows the normal principles of electrospray 
ionisation into the mass spectrometer12 
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1.3 Mass Analysers 
Ions generated by the various ionisation sources described in the previous section are 
detected by their different mass/charge (m/z) ratios. A range of MSI compatible mass 
analysers, each offering different mass accuracy, mass resolution, sensitivity and 
signal to noise ratio are available (Table 1). The main variants that have played a part 
in the research covered in this thesis are discussed, although many other 
combinations and hybrids are available42. 
Table 1: Comparison of different mass analysers used in MSI 
Analyser Resolving 
power 
Mass Range Mass accuracy 
(ppm) 
Acquisition 
frequency (Hz) 
ToF 103 - 104 0 – 20 kDa 1-5 >10 
Triple 
Quadrupole 
102 - 103 0 – 5 kDa 2 >100 
Orbitrap 
(QE) 
104 - 105 50 – 6 kDa 1 >10 
FTICR 104 – 106 20 Da – 10 
kDa 
≤1 >1 
 
High mass accuracy, usually expressed as parts per million (ppm) or essentially a 1 
mDa error margin on a mass measured at 1000 Da, combined with high mass 
resolving power, measured as mass at peak centre/width of peak at half height, is 
highly desirable when performing MSI analyses. The two terms are closely interlinked, 
with any degradation in one having a negative effect on the other43. Thousands of ion 
images can be generated during a single analytical run, high mass accuracy and 
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resolving power are required to deconvolute isobaric peaks or overlapping isotopic 
distributions within the resulting spectra44. 
Sensitivity and signal to noise ratio are largely governed by the sample that is being 
analysed and not the instrument hardware. Most commercially available instruments 
have inherently good sensitivity in ideal test conditions, however, when more complex 
biological matrices are analysed various factors such as ionisation suppression and 
salt content can vastly change the response and spectra obtained. 
 
1.3.1 Time-of-flight (ToF) mass analysers 
ToF mass analysers are arguably the most highly used instrument for MSI41,45,46. ToF 
analysers offer parallel, high detection efficiency, which leads to high inherent 
instrument sensitivity. Essentially ions are separated by their flight time in a field free 
region known as a flight tube. Mass to charge ratios are determined by measuring the 
time it takes for the ions to move through the flight tube and hit the detector and is 
governed by the following equation: 
m/z = At2 + B  
Where m/z is the mass/charge ratio, A is the calibration constant calculated by least 
squares fitting of a series of measured (arrival times) peaks of known m/z values, t is 
arrival time and B is a second calibration constant accounting for the velocity of the 
ablation plume. 
 
ToF instruments can have axial or orthogonal geometry. Axial instruments47 allow ions 
to directly enter the flight tube from the ion source and travel to the detector (Figure 
3). Orthogonal instruments48 transmit the ions generated from the ion source via ion 
24 
 
optics (often a quadrupole) to a pusher where the ion beam is deflected sideways into 
the flight tube and on to the detector (Figure 4). Many ToF mass analysers can operate 
in what is known as linear and reflectron modes, utilising two detectors (Figure 5), 
linear mode measures m/z ratio via flight time to detector one, whereas a ToF analyser 
operating in reflectron mode does not use detector one, instead ions are reflected back 
down the flight tube to a second detector via a series of ring electrodes, effectively 
doubling the length of the flight tube and improving resolution. The reflectron 
diminishes the spread of flight times of ions with the same m/z caused by differences 
in the kinetic energy of these ions, essentially allowing ions of higher energy (which 
have a longer flightpath) to reach the detector at the same time as lower energy ions 
at the same mass.   
 
Figure 3: A schematic of an axial time of flight mass analyser. Ions enter a high 
vacuum, field free region where they are separated by their flight time prior to 
detection. 
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Axial and orthogonal analysers can both operate in full scan only mode (MS) but some 
instruments are capable of performing tandem mass spectrometry experiments 
(MS/MS). Axial instruments can form product ions by the introduction of a collision cell 
directly into the flight tube, splitting the tube into two drift sections, this type of 
configuration is often referred to as a ToF/ToF instrument. The first drift section 
separates ions with the same flight time into different groups, entry into the collision 
cell is controlled by an ion gate that only allows passage of the desired precursor ion 
for subsequent collision induced dissociation fragmentation. Product ions then enter a 
second reflectron drift section where they are separated and detected. 
 
Figure 4: A schematic of an axial reflectron time of flight mass analyser capable 
of MS/MS showing the field free separation regions and the collision cell where 
precursor ions undergo collision induced dissociation. 
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Orthogonal ToF instruments generally use a quadrupole (discussed later) mass filter 
to select precursor ions generated in the source for entry to the collision cell prior to 
fragmentation. Product ions subsequently enter the flight tube for separation and 
detection. 
 
Figure 5: A schematic of an orthogonal reflectron time of flight mass analyser 
capable of MS/MS. The ion optics region used to select precursor ions is usually 
a quadrupole mass filter. 
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MALDI sources and ToF mass analysers are an ideal combination for performing mass 
spectrometry imaging experiments due to a variety of reasons. Probably the most 
significant is that the high duty cycle of the ToF analyser is perfectly coupled to the 
pulsed repetition rates (as high as 10 kHz) of the MALDI laser process. The ToF 
analyser allows all ions to be detected almost simultaneously giving it a distinct 
advantage over scanning mass analysers such as a quadrupole or ion trap instrument. 
ToF analysers can also be combined with DESI and LESA ion sources. 
 
1.3.2 Quadrupole mass analysers 
Quadrupole mass analysers49 consist of four parallel (ideally) hyperbolic rods (Figure 
6) that are used to electronically focus ions of a specific m/z ratio through the 
quadrupole. The opposing rods are electrically linked and specific radio frequencies 
and voltages are applied intermittently to induce oscillation of selected ions through 
the quadrupole region. Any ions that are not induced to oscillate assume an unstable 
trajectory and collide with the rods, resulting in the ions not being transmitted through 
the quadrupole. 
Quadrupoles are used in various hybrid mass analysers usually as mass filters for ions 
that are selected for subsequent MS/MS experiments, they are also, as the name 
suggests, and the main mass filter used in triple quadrupole instruments (QqQ). QqQ 
mass spectrometers are configured using Q1 and Q3 as mass filters whilst Q2 is 
operated in radio frequency only mode, Q2 can be flooded with an inert ‘collision’ gas 
allowing it to act as a collision cell for collision induced dissociation (CID) making 
MS/MS experiments possible. Mass resolution in quadrupole mass spectrometers is 
usually lower than that achieved in ToF instruments, typically around unit mass 
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resolution. QqQ instruments do however offer several different scan modes in addition 
to full scan mode. Precursor ion scanning, product ion scanning, constant neutral loss 
and selected reaction monitoring, the most commonly used scan mode on QqQ for 
MSI. Selected reaction monitoring mode offers high sensitivity, specificity and low 
signal to noise. QqQ instruments have been shown to be effective in MSI detection, 
and can be easily combined with MALDI, DESI and LESA ion sources50-52. 
 
Figure 6: A schematic of a typical quadrupole mass analyser. The quadrupole 
rods intermittently change polarity and radio frequency to induce ions of a 
selected mass to pass through to the detector whilst other ions are lost.  
 
 
 
 
1.3.3 Ion trap mass analysers 
There are three different types of ion trap mass analyser, 3D-quadrupole ion traps 
(Paul traps), Penning traps typically used in FTICR instruments (discussed later) and 
Kingdon traps used in instruments such as the Orbitrap™. 
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All ion trap mass analysers operate by storing ions in the trap and by using carefully 
timed changes in voltage, magnetic field and radiofrequency to manipulate the ions 
and ultimately deliver them to the detector. Ion traps have the ability to perform MSn 
experiments, allowing acquisition of CID data on a particular ion followed by its product 
ions and any ions resulting from further CID of those product ions, this differentiates 
ion traps from other mass analysers such as the ToF and QqQ. 
Orbitrap based instruments such as the Q-Exactive (Figure 7) offer high mass 
resolving power (up to 140K at m/z 200) and good mass accuracy. They are 
increasingly being used in conjunction with DESI ion sources for MSI. The Orbitrap 
consists of two outer electrodes around an interior spindle shaped electrode 
connected to independent voltage supplies. The space between the electrodes is at 
high vacuum. A voltage can be applied to the outer and inner electrodes creating an 
electric field that can be used to focus the ions in the direction of the central spindle 
electrode, the circular motion of the ions creates an opposing centrifugal force. An 
applied axial electric field guides the ions to the widest part of the central spindle 
creating oscillations concurrently with the circular motion. The outer electrodes 
measure the ion current in the time domain which is Fourier transformed into the 
frequency domain then converted into a mass spectrum53. 
Ion trap mass spectrometers can be used with MALDI, DESI and LESA ion sources 
for MSI analysis. 
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Figure 7: A schematic of a Q-Exactive mass spectrometer with an Orbitrap mass 
analyser. The Q-Exactive incorporates a quadrupole mass filter, collision cell 
and Orbitrap allowing both MS/MS analysis and MSn. 
 
 
 
 
1.3.4 Fourier transfer ion cyclotron resonance (FTICR) mass analysers 
FTICR mass analysers are becoming increasingly popular for MSI experiments and 
widely used in pharmaceutical MSI R&D. FTICR instruments are capable of extremely 
high mass accuracy and resolving power. FTICR-MS offer new identification strategies 
that are not reliant on fragmentation, the superior mass resolution offered by the 
instruments allows identification of unknown structures by elemental composition54. 
FTICR fundamentals are complex and are extensively covered and reviewed 
elsewhere55, only the basics are covered here. 
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FTICR instruments consist of an ICR cell located in the centre of a super-conducting 
magnet which provides a stable and uniform magnetic field. Ions can undergo 
cyclotron motion in a stable magnetic field, this motion causes the ions to travel in a 
circular orbit with a frequency that is dependent on the ions mass. 
A typical open cylindrical ICR cell (Figure 8a) consists of several sets of plates known 
as trapping electrodes, excitation electrodes and detection electrodes. Ions are 
trapped in the ICR cell by applying a small voltage to the trapping electrodes at either 
end of the cell. A sweeping radio-frequency potential is applied to the excitation 
electrodes at a resonant frequency covering all of the ions in the cell, the ions are 
excited into cyclotron motion with increasing orbital radius (Figure8b) until they either 
hit the walls and are neutralised or the RF potential is switched off, at which point the 
ions continue to oscillate and generate a small electric field on the detection 
electrodes. The data is Fourier transformed from time to frequency domain data from 
which a m/z ratio can be mathematically calculated. 
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Figure 8: A schematic of Fourier transform ion cyclotron mass spectrometry a) 
A typical open cylindrical cell where ions are trapped and excited into cyclotron 
motion, b) Typical Excite/Detect geometry with an ion in cyclotron motion. 
 
 
 
Most FTICR Instruments such as the Bruker SolariX FTICR combine a quadrupole 
analyser and collision cell with the ICR cell to allow ion isolation, accumulation and 
MS/MS analysis. Fragmentation can also be done in the ICR cell itself after the 
introduction of a suitable gas to promote Collision Induced Dissociation (CID). A 
relatively new introduction to the SolariX platform is Continuous Accumulation of 
Selected Ions (CASI®)56, this technique has shown results of up to 10-fold higher 
sensitivity in comparison with full scan acquisition mode. The CASI mode separates 
targeted ions from any chemical background noise generated from the sample thereby 
lowering the limit of detection for the analytes. FTICR instruments are typical used with 
ESI57 and MALDI ion sources58 but can also be linked to LESA. 
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1.4 Sample preparation 
Sample preparation is an important factor when embarking on any MSI analysis37. It 
is essential to adhere to strict sample collection protocols to maintain tissue integrity 
and minimise any endogenous or exogenous compound degradation within the tissue. 
Fundamentally MSI analysis requires a flat surface to sample from, so cryomicrotome 
sectioning under controlled temperature conditions must be performed. DESI and 
LESA analysis require little sample pre-treatment other than cryomicrotome sectioning 
prior to standard analysis, although occasionally all MSI techniques benefit from 
sample washing to remove lipids and salts. Further sample pre-treatment may be 
required to aid detection such as proteolytic digestion or chemical derivatisation. 
MALDI-MSI additionally requires the coating of a matrix across the tissue to promote 
ionisation, this essential step needs careful consideration of factors such as matrix 
choice, analyte extraction, analyte delocalisation and what spatial resolution is 
required. Matrix selection, wetness and thickness can take several iterations to fully 
optimise but with automated systems can be performed reproducibly. The specific 
considerations of MALDI sample preparation are discussed later. 
 
1.4.1 Sample collection and storage 
MSI is best performed on fresh, snap frozen tissue. Snap freezing can be carried out 
in several different ways to ensure adequate maintenance of the tissue structure and 
minimal degradation. Essentially different solvent systems can be used to exert 
different temperatures on the tissue to ensure no tissue fracturing occurs. 
Tissues must be snap frozen free floating to avoid any deformation caused by the 
solvent container. Several different solvents can be used in MSI sample collection but 
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typically liquid nitrogen (LN) and dry-ice chilled isopentane (IP) are employed 
depending on the size of the tissue being frozen. Generally small organs or tissue 
samples can be snap frozen by free floating in LN. Dry-ice chilled IP offers a faster 
rate of cooling, so is more suitable for larger tissues. Often the freezing rate for more 
fragile tissues can be too quick so an alternative to IP such as isopropyl alcohol can 
be used to bring the temperature down more slowly, this is often followed by a short 
time submerged in LN or IP to bring the temperature of the tissue closer to -80°C. Care 
must be taken to adequately dry the frozen tissue to ensure no residual solvent is left 
on the sample that could compromise any subsequent sectioning. 
Whole body samples can be frozen in dry-ice chilled hexane. Freezing whole body 
samples can be a lengthy process often taking as long as 15 mins due to the insulating 
effect of hair, fat and the outer organs resulting in the risk of continuing metabolic 
processes59. 
MSI tissue samples are usually stored at -80°C post snap freezing. The samples have 
been shown to be stable for approximately a year60, after this period effects on protein 
and peptide stability has been reported61. 
 
1.4.2 Other stabilisation methods and formalin fixed paraffin embedded 
samples 
Formalin fixed paraffin embedded (FFPE) samples are the mainstay of traditional 
histology and as such, extensive libraries of tissue samples exist around the world 
offering a massive opportunity for MSI analysis to have an impact on the etiology of 
disease. Successful MSI analysis has been reported using FFPE samples but results 
have largely been in the area of proteomics39,61-63. Extensive covalent cross linking 
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within proteins in FFPE samples is a significant challenge for MSI analysis. Concerns 
also exist within the MSI community about delocalisation of smaller molecules and 
drugs brought about by the formalin fixation process itself and the de-waxing process 
that is needed prior to analysis. FFPE tissues have however been shown to be 
effective in lipidomic analysis64,65, where no signs of delocalisation or interference 
where observed, despite the higher prevalence of sodium adduct ions arising from the 
buffers used in the formalin fixation process. 
Although snap frozen tissue is considered stable when stored at -80°C cellular 
degradation restarts when the sample is thawed (when thaw mounting for example)66. 
A method pf preventing proteolytic activity by rapid heating under vacuum to denature 
tissue proteins and enzymes has been developed36,67,68. This method has seen some 
success but concerns still exist with respect to post stabilisation tissue quality69. 
Incorporation of preservation solvents into MALDI matrices has also been explored as 
a histologically relevant way of simultaneously stabilising (fixing) the tissue and 
depositing the MALDI matrix enabling subsequent proteomic analysis70,71. 
 
1.4.3 Tissue embedding 
The time spent cryo-sectioning tissues individually at moderate low temperature (~ -
20°C) can sometimes lead to molecular and optical changes to the tissue sections, 
sometimes called ‘freezer burn’. Furthermore, some tissues are small and quite fragile 
making them hard to cryo-section, it is therefore often necessary to embed several 
tissues from the same study in a supportive embedding media. Several different 
embedding media have been successfully used with MSI. Gelatin and 
carboxymethylcellulose (CMC) are widely used. Optimal cutting temperature (OTC) 
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media has been used with MSI but severe ion suppression has been observed in 
several studies as the media coats the cutting blade of the cryostat and contaminates 
the sections72. Recently a new embedding media Poly[N-(2-
hydroxypropyl)methacrylamide] (pHPMA) has been developed especially for MSI 
application73. pHPMA has some excellent physical properties making it a good 
embedding media, unlike other media it is a liquid to around -8°C thus minimising the 
chance of any outer thawing of the tissue during the embedding process. Practically, 
pHPMA cuts very nicely on the cryostat and maintains a solid support around the 
tissue. It has also been shown to have little or no ion suppression effects when used 
for MSI. 
Figure 9: Figure showing several rat kidneys embedded in pHPMA prior to 
sectioning. The embedding media allows simultaneous sectioning of multiple 
tissue at the same time, maintaining tissue structure and reducing time spent in 
the cryostat. 
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1.4.4 Cryo-sectioning, post sectioning stabilisation and section storage 
Cryo-sectioning is an important part of MSI sample preparation. Tissue sections are 
produced from frozen tissue in a cryomicrotome or cryostat, the tissue is usually 
mounted onto the cryostat cutting block using a small amount of distilled water. 
Sections are usually taken at around 10-20 µm thickness and thaw-mounted (gentle 
warming of the slide under surface) onto glass microscope slides for DESI, LESA and 
MALDI-MSI or indium tin oxide (ITO) coated glass slides for MALDI-MSI on axial ToF 
instruments. Stoeckli et al. described the optimum tissue thickness for MSI as being 
12 µm74, although tissue thicknesses ranging from 3-50 µm have been reported38.  
Tissue orientation and cutting depth are sectioning parameters that should be 
considered prior to embarking on an experiment. Thought should be given to which 
geometry e.g. sagittal or coronal sectioning will most easily show the required organ 
features to answer the questions being posed. 
Temperature is another sectioning variable that needs to be controlled to allow 
production of the highest quality sections possible. The temperature at which sections 
are cut is tissue dependant but generally ranges between -15 to -25°C. In our 
laboratories we generally cut sequential sections for DESI, MALDI, LESA and 
histology all at the same time to minimise any potential disorientation caused by 
remounting the sample at a later date. Sections should be randomised as much as 
possible on the slide to eliminate any degradation bias caused by time in the cryostat. 
Once a section has been cut, it can be dried/desiccated in a stream of nitrogen prior 
to re-freezing for the addition of further sections. This process stops any build-up of 
frost on the slides, minimising delocalisation by surface water when the slide is brought 
back to room temperature, it also stabilises small endogenous metabolites within the 
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tissue. Once the required sections are cut and the final drying process completed the 
slides can be vacuum packed and stored at -80°C in individual slide mailers to 
minimise any freeze/thaw cycles when the slides are used. Care should be taken when 
removing the slides from -80°C storage to allow the slides to reach room temperature 
prior to breaking the vacuum pack seal, again minimising any condensation build-up 
that could cause delocalisation. 
 
1.4.5 Sample washing 
Washing mounted sections to remove lipids and salts in order to increase sensitivity 
and reduce ion suppression has been reported to be effective in the analysis of 
proteins and peptides60,72,75,76. Washing procedures in general should be avoided 
when analysing small molecules such as drugs, although some successful washing 
approaches have been applied to such molecules by Shariatgorji et al.77. Ammonium 
salt solution washes have been used to to enhance the sensitivity of negative ion 
MALDI-MSI lipid analysis78. 
 
1.4.6 On-tissue tryptic digestion 
Protein and peptide analysis are not the focus of this thesis but it is relevant to mention 
that intact proteins can be detected with reasonable sensitivity up to around the 25-30 
kDa mass range. It is also possible to detect larger proteins by using on-tissue 
enzymatic digestions (generally carried out using the enzyme trypsin), effectively 
cleaving the larger proteins into their constituent peptides. A good review of the 
relevant techniques has been published by Diehl et al.79 
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1.4.7 On-tissue chemical derivatisation 
On-tissue chemical derivatisation has been recognised as a good method for 
enhancing analyte sensitivity and detection in MSI analysis. Derivatisation reagents 
are liquids so concerns exist about the impact on MSI images caused by delocalisation 
of the analytes. Its popularity has however grown over recent years, with methods 
being largely based on established LC-MS derivatisation procedures. The reaction 
schemes are usually functional group specific and have been applied to various 
different chemical classes including peptides80, N-glycans81, amino acids82, steroids83 
and drug molecules84. Building on this success, MALDI-MSI researchers have found 
compounds that can act as both an on-tissue derivatisation reagent and a MALDI 
matrix85-87. 
 
1.4.8 MALDI matrix selection 
Matrix selection is an essential step in MALDI-MSI sample preparation. Successful 
detection of analyte molecules is dependent on which matrix is applied to the sample. 
An ideal matrix should absorb UV light at the appropriate laser wavelength and be able 
to isolate and extract the analytes under investigation, it should also not sublime under 
vacuum, it should be a proton acceptor or donator and its solubility should be high in 
the same solvents as the analytes. Small organic molecules work well, many have 
been evaluated over the years, a list of commonly used matrices can be found in Table 
2, along with typical applications and operating polarity. 2,5-dihydroxybenzoic acid 
(DHB), α-cyano-4-hydroxycinnamic acid (CHCA), 9-aminoacridine (9AA) and 1,5-
diaminonapthalene (DAN) are the most commonly used for pharmaceutical 
applications because of their ability to extract and ionise small endogenous 
40 
 
metabolites, drugs and lipids. In an industrial R&D environment it is often not possible 
to screen large numbers of matrices for compatibility with new chemical entities, 
instead ionisation testing is limited to the four main matrices listed above, if none are 
found to be effective alternative imaging platforms such as DESI and LESA-MSI are 
then attempted. 
The solvent system used to dissolve a matrix is another parameter that can effect 
analyte extraction. Typically 50 – 80% v/v mixtures of acetonitrile, methanol, ethanol 
and water are used with a small amount of organic acid such as trifluoroacetic acid60 
(0.1-1% v/v) for proton enrichment in positive ion mode. The amount of organic acid 
used can greatly influence the spectra obtained from direct tissue analysis so careful 
optimisation is required. Matrix concentration usually ranges between 5-50 mg/mL 
depending on the matrix being used. 
Table 2 List of typical MALDI-MSI matrices for different applications and 
polarities 
Matrix Molecular 
Weight 
(Da) 
Ionisation 
mode 
Typical 
applications 
References 
2,5-dihydroxybenzoic 
acid 
154.1 Positive Drugs, lipids, 
peptides 
88-90 
α-cyano-4-
hydroxycinnamic acid 
189.1 Positive Drugs, peptides, 
Oligonucleotides 
90,91 
9-aminoacridine 194.2 Negative Lipids, drugs 92-94 
1,5-diaminonaphthalene 158.2 Negative Amino acids, 
lipids 
95-97 
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Sinapinic acid 224.2 Positive Proteins 90,98 
2-mercaptobenzothiazole 158.2 Positive Lipids 99,100 
2,6-
dihydroxyacetophenone 
152.1 Positive Lipids 45,101 
2,4-
dinitrophenylhydrazine 
198.1 Positive peptides 61,102 
 
 
1.4.9 MALDI matrix application 
Matrix deposition for MALDI-MSI analysis should be carefully considered. Any method 
should ensure a homogeneous coverage of the tissues to be studied to minimise 
variations in response in different regions of the sample. Crystal size is all important 
when performing MSI, if the crystals are too large this will affect the spatial resolution 
that can be achieved with the analysis. Crystal sizes as low as 1 µm have been 
reported103 but typical matrix crystal sizes of between 5-150 µm are more usual 
depending on the deposition method. The deposition method must also be 
reproducible to ensure high quality images are produced and inter slide comparison in 
larger studies or across different laboratories can be performed. The main matrix 
deposition methods available will be discussed below. 
Matrix can be deposited in various different ways, with the most commonly reported 
being administration by pneumatic nebulisation. This can be done manually with the 
use of a pneumatically assisted thin layer chromatography sprayer or airbrush or 
matrix deposition can be done robotically with various commercially available systems 
such as the TMsprayer (HTX Technologies, Chapel Hill, NC, USA) or the SunCollect 
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sprayer (SunChrom, Friedrichsdorf, Germany). All use the common principle of 
multiple, differing direction, passes across the slide to deposit the matrix. These 
systems are rapid and highly reproducible but as always require method optimisation 
for each matrix being applied, measures must be taken to ensure the application is not 
too wet as any accumulation of surface solvent could result in delocalisation of the 
analytes within the tissue. Pneumatically assisted sprayers can also suffer from 
intermittent blockages, altering the amount of matrix being dispensed, so rigorous 
instrument hygiene procedures must be adhered to.  
Other methods of depositing liquid matrices include piezoelectric104 and acoustic 
spotters105 which can dispense pL volumes of matrix, they typically produce matrix 
spots in the region of 100-150 µm spot centre to spot centre so limit the spatial 
resolution of any subsequent analysis. An automated system based on vibrational 
vaporisation (ImagePrep, Bruker Daltonics, Bremen, Germany) is commercially 
available offering droplet sizes of ~20 µm, it comes with an optical sensor to control 
deposition periods and intervals, matrix layer thickness, wetness and drying rate in 
real time106. 
In addition to these ‘wet’ application techniques there are also several ‘dry’ application 
techniques worthy of note. Matrix sublimation has grown in popularity over recent 
years, as advances in laser technology lead to reduced laser beam diameter (min. 5 
µm) and increased laser repetition rate (max. 10kHz). Higher spatial resolution 
imaging is becoming a viable and valuable asset to the researcher as biological 
processes become more focussed on changes at the cellular level107. Sublimation 
offers a rapid, robust and dry way of homogeneously coating slides with matrix, 
importantly the crystal size achieved can be in the low micron region, making high 
resolution analysis possible108 and the solvent free nature of the technique minimises 
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any potential delocalisation of analytes. The equipment needed to make sublimation 
apparatus is readily available, with most industrial and academic groups building in-
house kits at low cost109. Commercially available sublimation instruments have 
recently been introduced, notably the iMLayer™ (Shimadzu, Cheadle Hulme, UK). 
Such instruments offer a viable alternative to home-built apparatus but are fairly 
expensive to acquire and concerns exist over inter matrix contamination. Sublimation 
protocols need to be strictly controlled in terms of time, vacuum (pressure and 
duration) and matrix amount and must be developed for each different matrix95,110. 
A further ‘dry’ matrix deposition method is dry coating. This simple method involves 
milling the dry matrix crystals using a mortar and pestle and subsequently passing 
through a fine sieve onto the tissue sections111. A drawback of dry matrix application 
techniques is that the absence of a liquid interface does not allow extraction of analytes 
into the crystals from the tissue surface, making the techniques unsuitable for some 
applications. However it has been successfully applied to detection of drugs in tissues 
that were undetectable by standard matrix application112. Ferguson et al. have built 
upon the dry matrix application method for forensic applications, developing a ‘dry-
wet’ application method when preparing and analysing latent fingermarks my MALDI-
MSI113. 
All of the matrix application techniques discussed are usually performed post-
sectioning, however, some academic groups have developed processes that use 
slides pre-coated with sublimated matrix prior to sectioning114. Crystal sizes of 1-2 µm 
are reported. The advantage of this procedure versus post-sectioning sublimation is 
that the tissue sections become wet on thaw mounting allowing analyte extraction 
making the process more widely applicable. 
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Matrix deposition quality control is important and can easily be done simply by 
weighing the slide before and after coating or by measuring the optical transparency 
throughout the application process8, crystal size can be checked using an optical 
microscope, ensuring reproducibility from slide to slide. 
 
1.5 Quantitative MSI methods 
MSI has rapidly developed into a valuable and versatile technique for exploring 
molecular distributions in animal tissues. This qualitative data gives the researcher 
valuable insight, especially in pharmaceutical R&D where quick and robust 
assessments of a drug or metabolite distribution can confirm efficacy in a target tissue 
at an early stage or accumulation in tissue where toxicity has been encountered. 
Scientists within industry have become familiar with the kind of qualitative information 
MSI offers but require quantitative information to calculate parameters like dose to 
man predictions, pharmacodynamic models of efficacy and the assessment of drug 
toxicity thresholds. Quantitative MSI (qMSI) is an area of considerable research at the 
moment, simultaneous extraction of both qualitative spatial distribution information 
and quantitative exogenous/endogenous compound levels has been shown to be 
possible but has proven to be difficult in practice, largely because of ion suppression 
effects caused by the changing molecular environments within complex tissue 
sections. Numerous methods of qMSI have been reported, most follow a tried and 
tested formula of spotting a calibration standard111 or set of calibration standards112,115 
onto control tissue which is then run alongside any unknowns. Further quantitative 
methods have been reported that utilise tissue mimetics17,116,117 or surrogates118, 
essentially tissue homogenates or an inert media such as gelatin with varying levels 
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of the analyte spiked into them prior to freezing, sectioning and analysis at the same 
time as the unknowns. Alone these methods offer relative quantitation but do not 
contend with the issues of variable MS response caused by ion suppression effects or 
local variations in analyte extraction. In order to address this complex factor most 
methods have adopted different normalisation strategies to provide absolute 
quantitation. 
 
1.5.1 Normalisation 
Arguably the most accepted method of qMSI normalisation utilises a stable isotope-
labelled version of the analyte or a structurally similar compound to the analyte as an 
internal standard (IS). The IS is mixed with the matrix solution and homogeneously 
sprayed over the slide prior to sectioning119 or over the tissue sections after sectioning 
and calibration standard addition15. The IS can then be used for the pixel to pixel 
correction of the analyte intensity (calculated as analyte intensity/IS intensity) across 
the tissue sections. Pirman et al. reported using a deuterated version of acetyl-L-
carnitine (AC) applied prior to sectioning when quantifying endogenous levels of AC 
in piglet brain tissue120. The principle was successfully used again for the quantitation 
of cocaine in human brain tissue sections121. Prideaux et al. used Levofloxacin as a 
structurally similar analogue as an internal standard for the quantitation of moxifloxacin 
in lung tissue taken from a rabbit tuberculosis model122. Addition of IS and calibration 
standards prior to and after sectioning has recently been explored by Chumbley et al. 
who explored different matrix and calibration standard addition protocols using an 
acoustic spotter to in vitro dosed rabbit liver tissue sections119. Post-sectioning addition 
of the standards, stable-labelled IS and matrix was found to be the optimum sequence 
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for ripaficin quantitation, results generated by MSI correlated well with those generated 
by LC-MS/MS. 
Although pixel to pixel normalisation with a stable-labelled version of the analyte is the 
gold standard of absolute quantitation in qMSI, several groups have used alternative 
normalisation methods in qMSI analysis. Takai et.al. used a representative DHB matrix 
peak to normalise the response of octreotide, a therapeutic peptide, when quantifying 
in mouse liver and kidney118. Concentrations calculated using DHB normalisation 
compared favourably with those determined by LC-MS/MS. Tissue specific 
endogenous marker compounds have also been used to normalise drug response in 
qMSI. Wang et al. reported using an endogenous brain tissue peak when analysing 
the distribution of chlorisondamine in rat brain sections123, although concerns exist that 
such endogenous markers are not evenly distributed throughout the tissue biasing any 
data that is normalised against them. 
Hamm et al. reported the novel use of a tissue extinction coefficient (TEC) when 
quantifying olanzapine and propranolol in rat and mouse whole body sections by 
MALDI-MSI124. This technique involves spraying a homogeneous amount of a 
compound mixed with the matrix over control whole body tissue sections. Once 
analysed the TEC can be calculated for different organ regions of the section by 
dividing the average intensity of the compound on tissue by the average intensity of 
the compound on the glass slide. The regional TEC values can then be used to scale 
the intensities obtained in dosed tissue, which in turn can be back calculated against 
an adjacent, off-tissue, spotted calibration range. 
A summary of the different qMSI methods is presented in Table 3. 
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Table 3 Summary of different qMSI methods used to quantify drugs in tissues 
Drug Normalisation Calibration 
Curve 
Tissue MSI 
Platform 
Validated 
by LC-
MS/MS 
Ref. 
Clozapine None Yes, control Brain (rat) MALDI ✓ 125 
Cocaine Stable-label Yes Brain (human) MALDI ✓ 121 
Erlotinib None Yes, mimetic Liver (rat) LESA/ 
DESI 
✓ 17 
Lapatinib Stable-label Yes, mimetic Liver (dog) MALDI ✓ 116 
Moxifloxacin Non Yes, mimetic Liver (rat) LESA/ 
DESI 
✓ 17 
Olanzapine TEC 
None 
Yes 
Yes, mimetic 
Whole body (rat) 
Liver (rat) 
MALDI 
LESA/ 
DESI 
✓,✓ 17,124 
Octreotide Matrix peak Yes, gelatin Liver, kidney 
(mouse) 
MALDI ✓ 118 
Paclitaxel Stable isotope Yes Licer, spleen, tumour 
(mouse) 
MALDI ✓ 126 
Propranolol TEC Yes Whole body (mouse) MALDI ✓ 124 
Raclopride Compound IS Yes, mimetic Liver (mouse) MALDI ✓ 127 
Rifampicin Stable-label Yes Liver (rabbit) MALDI ✓ 119 
Terfenadine None 
None 
Yes 
Yes, mimetic 
Whole body (rat & 
mouse), Liver (rat) 
MALDI 
LESA/ 
DESI 
✓, x 17,128 
Tiotropium TIC Yes Lung (rat) MALDI ✓ 115 
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Triamcinolone 
acetonide 
Stable label Yes Cartilage MALDI ✓ 129 
 
1.6 Data processing 
Sample preparation and subsequent acquisition of multiplex mass spectrometry data 
from MSI experiments is a complex process, however, this is a precursor to data 
processing and analysis that is needed to generate images and interrogate the data. 
MSI data files are often tens of gigabytes (GB) in size and can be as large as 100 GB 
in older instruments, creating data storage problems and making data handling slow 
and difficult. Instrument vendors have developed platform specific data processing 
software solutions that allow scientists to create images and perform limited 
multivariate analysis. Vendor software packages concentrate on bringing together the 
spatial coordinates with the spectral data acquired in the analysis and generate a 
colour map image based on the relative abundance of the peak of interest in the mass 
spectrum. This has several drawbacks, foremost the software is designed to process 
data from the vendors specific file type, rendering it unsuitable for multimodal imaging 
workflows that adopt different MS platforms and secondly, the software solutions don’t 
allow any additional data processing options to enable further data mining. 
The MSI community have introduced a common data format designed especially for 
MSI analysis. Imaging mass spectrometry mark-up language130,131 (imzML) has been 
embraced by scientists eager to use more sophisticated data processing techniques. 
Most instrument vendors now provide imzML convertors embedded into their own 
software and various academically derived convertors are available that can be used 
to convert older data formats132. The advantage of this data conversion is that imzML 
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files can be read by a multitude of different MSI software packages and furthermore 
data can be easily shared between collaborating institutions. 
Various imzML capable software suites are now available as freeware. Robichaud et 
al. published a report on an open source interface to visualise MSI data called 
MSiReader based on Matlab, a popular multi-paradigm numerical computing 
environment133. MSiReader is constantly evolving134 and has found widespread use 
with both MALDI and DESI-MSI data. SpectralAnalysis is another visualisation 
software that operates within a Matlab environment135. It is versatile software, offering 
an entire data processing workflow including data smoothing, baseline correction, 
normalisation, and image generation to multivariate analysis (eg principal component 
analysis (PCA), non-negative matrix factorisation (NMF), maximum autocorrelation 
factor (MAF), and probabilistic latent semantic analysis (PLSA))136. The software can 
be used for single experiment data sets and large multi-instrument, multimodality, and 
multicenter studies. MSiQuant is a purpose built quantitation software package that is 
also available as freeware137. It allows the user to select regions of interest (ROI) 
around calibration spots typically used in qMSI workflows. ROI are then used to 
generate mean relative abundances and calibration curve generation for the back 
calculation of unknowns. Baseline corrections, subtractions, denoising, smoothing, 
recalibration and normalisation can all be performed within the software. 
In addition to the various types of freeware available to MSI scientists, several 
companies have developed powerful software for MSI data processing. Notable 
among these companies are Bruker and ImaBiotech. Bruker market a MSI software 
solution called SCiLS Lab. This is an extremely powerful software suite originally 
confined to data generated on Bruker MS platforms but now avaiable as multivendor 
software based on the imzML format. It enables users to perform regular targeted data 
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analysis but offers a variety of different options to perform downstream untargeted 
data processing such as spectral segmentation, discriminative RoC analysis and 
tissue classification using models based on training data138. 
 
1.7 Complementary optical techniques 
It is often necessary to co-register MSI data with classical histology data in order to 
differentiate the heterogeneous cell populations in complex tissues. The integration of 
histology and MSI is well documented139. Staining can be performed on tissue sections 
prior to MSI analysis, however, careful attention must be given to the compatibility of 
the staining protocols with mass spectrometry techniques. Staining with reagents such 
as methylene blue or cresyl violet have been applied in this way139,140. Typically 
histological staining is performed post analysis. Non-destructive DESI-MSI analysis 
lends itself well to this protocol although staining post MALDI-MSI requires pre-staining 
removal of the MALDI matrix. This can be done by gently washing the slide in a 70% 
ethanol solution to dissolve the deposited matrix, the sections can then be dehydrated 
by submerging the slide in a sequence of increasing ethanolic solutions72. Staining the 
slide that has been analysed by MSI represents the best way to ensure accurate co-
registration, although, some damage can occur to the tissue during analysis. It is 
therefore regular practice to take adjacent sections for staining either before and/or 
after the one being analysed141, although accurate co-registration may be difficult post 
analysis due to the differences in the structure and cellular morphology of the adjacent 
sections, especially when performing high resolution MSI. 
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1.7.1 Haematoxylin and eosin staining 
Haematoxylin and eosin (H&E) staining is the most common staining procedure used 
in pathological examination. Haematoxylin is a violet coloured stain that is used to 
stain basophilic substances that carry a negative charge such as DNA/RNA in the 
nuclei of cells. Eosin, in contrast is a pink stain that is used to stain acidophilic 
substances with a positive charge such as amino acids, it thus highlights intracellular 
membranes and cytoplasmic filaments that often contain amino acid residues. 
H&E staining in MSI experiments is generally carried out post analysis or on adjacent 
sections as it interferes with the MS response and the subsequent observed mass 
spectra140. H&E staining has been employed extensively alongside MSI data in the 
classification of different tumour species at the molecular level by MALDI-MSI142-144 
and DESI-MSI145,146.  
 
1.7.2 Immunohistochemical staining 
Immunohistochemistry (IHC) is the selective staining of antigens within the cells of 
tissues using antibodies147 that are specific for a particular cellular marker. It is used 
in pathology to understand and highlight the distribution and location of biomarkers in 
different regions of tissue. The antibodies are usually labelled with a reporter molecule 
that can change colour or has the ability to fluoresce for selection. The technique has 
been widely used to complement MSI analysis in the areas of oncology148 and 
nephrotoxicity149. 
Imaging mass cytometry is an emerging technique based on laser ablation inductively 
coupled plasma mass spectrometry (LA-ICP-MS)150. Antibodies are raised to target 
specific molecular species within tissues (based on the same principles as IHC), the 
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antibodies can be labelled with metal isotopes such as gold which in turn can be used 
as reporters for detection by LA-ICP-MS (often referred to as cytometry by time of 
flight or CyToF). Cocktails of antibodies labelled with different metals can be used to 
‘stain’ a tissue section making the technique both specific and multiplex151. The 
technique has already been used to map the distribution of cisplatin in various tissues 
including tumour152. Imaging mass cytometry offers much promise for the future in 
pharmaceutical R&D where the trend is towards development of large molecule drugs 
and drugs based on new modalities such as micro-RNA. 
 
1.8 Validation of MSI against other techniques 
When a new analytical technique begins to make progress from an interesting idea to 
use in academia and subsequent commercialisation it must be compared and 
validated against a technique that performs a similar role. MSI is no exception and has 
been extensively validated against alternative imaging technologies such as qWBA 
and quantitatively against LC-MS/MS based homogenate analysis. These are 
considered the ‘gold standard’ techniques over which MSI should offer enhanced or 
superior analytical properties. qWBA is a radio-labelled based analytical technique that 
is used to spatially map the distribution of drugs in tissues. The main drawback of the 
technique is that the radio-labelled version of the drug can undergo metabolism in vivo 
and subsequently form a labelled metabolite that confuses the distribution profile of 
the parent drug making the data ambiguous. Homogenisation analysis by LC-MS/MS 
is extensively used to provide researchers with tissue concentrations but the technique 
results in the loss of all spatial information within the tissue. MSI has the potential to 
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complement these two techniques offering quantitative, label free distribution data. 
Validation of MSI against the different techniques will be discussed further below. 
 
1.8.1 Validation vs. Quantitative whole body autoradiography 
Comparison of MSI data with traditional qWBA data has been extensive. Hsieh et al. 
first reported a good correlation between MSI data generated by MALDI-ToF and 
qWBA in the analysis of clozapine in rat brain tissue, even going a step further and 
comparing the intensity difference in different areas of the brain to the concentration 
differences observed by HPLC-MS/MS125. Kertesz et al. similarly compared the 
distribution of propranolol in rat whole bodies sections by DESI-MSI and qWBA. This 
showed nominal agreement between the relative abundance of the drug by DESI and 
the amount of radioactivity detected by qWBA in brain, lung and liver tissue. Kidney 
tissue however showed a disparity between the two techniques that could possibly be 
attributed to accumulation of a metabolite and subsequent detection of the radiolabel 
by qWBA, DESI-MSI however failed to detect the metabolite153. Drexler et al. 
compared the two techniques when analysing a proprietary drug in rat eye observing 
a good correlation between the generated images with the drug largely localised in the 
retina and uveal tract. MSI was used to confirm the absence of major metabolites 
contributing to the radiographic image154. More recently Goodwin et al. reported the 
comparison of a therapeutic cyclic peptide distribution in mouse kidney by MSI and 
qWBA, showing that the qWBA results were subject to a contribution from two labelled 
metabolites of the drug. Results were further complicated by isotopic overlay of one of 
the metabolites with the parent drug on a MALDI-ToF instrument. The MSI analysis 
was repeated using a high spectral resolution MALDI FT-ICR instrument which 
resolved the isotopic peaks by accurate mass155. 
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1.8.2 Validation vs. LC-MS/MS 
As highlighted in section 1.4 quantitative MSI methodology is an area of focus for the 
scientific community and as such extensive comparisons have been reported between 
qMSI and LC-MS/MS homogenisation methods. Table 3 in section 1.4.1 lists the 
various methods and drug compounds that have been validated by subsequent LC-
MS/MS homogenate analysis. It should be highlighted that most of these methods 
have used tissue that is fairly homogeneous in nature such as liver as a direct 
comparison due to the loss of spatial information in the homogenate analysis. 
Comparison of MSI data in more complex tissue types with LC-MS/MS is much harder 
due to the potential localisation of drugs into different regions of the tissue. Validation 
in these complex tissues has been reported, Frank et al. used tissue microdissection 
to validate MALDI-MSI data mapping the protein expression difference in different 
regions of the rat brain156. Goodwin et al. also used tissue laser microdissection 
followed by LC-MS/MS to validate the distribution data for a compound generated by 
MSI in rat brain sections111. 
 
1.9 Application of MSI in Pharmaceutical Research and Development 
Pharmaceutical Research and Development (R&D) is a lengthy, costly and 
competitive business. Potential new drugs can take as long as ten years to reach 
commercialisation, at a cost of billions of dollars, furthermore, attrition rates during the 
later stages of development increase the already high risk factors involved with taking 
a new compound into the clinic. Pharmaceutical companies have gone to great lengths 
to decrease these high failure rates, minimising risk in an effort to maximise reward 
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and bring life enhancing medicines to patients. Poor efficacy and toxicity are the main 
reasons for high attrition rates within R&D157,158. The industry has addressed this 
problem by adopting a strategy of early, accelerated compound optimisation with 
parallel generation of physicochemical and pharmacokinetic properties to design safer 
and more efficacious drug candidates that maximise therapeutic index whilst 
minimising any risk of toxicity. 
Bioanalytical techniques such as LC-MS have kept pace with the need for higher 
throughput but are limited in value when trying to assess a drugs distribution in vivo. 
Traditionally drug distribution studies were performed during the later stages of 
development using radiolabelled compounds in low throughput techniques such as 
qWBA or homogenisation studies using long liquid chromatography gradients. MSI, 
whilst not replacing any of these established methods is increasingly being used to 
complement these approaches and provide timely and cost effective insights into the 
deposition and fate of new chemical entities. The application of the technique has been 
expanded further to encompass endogenous compound changes as markers for drug 
induced efficacy or toxicity and to bring insight into novel drug delivery technologies. 
 
1.9.1 Drug distribution and efficacy 
In order for a drug to exert a pharmacological response it needs to be present at the 
site of action in sufficient quantities and for the necessary time to elicit efficacy. If the 
drug concentrations are too high this can induce toxicity. Drug distribution studies are 
therefore integral to the pharmaceutical R&D pipeline. Troendle et al. were the first to 
demonstrate the applicability of MALDI-MS to drug compounds directly from tissue 
sections159, successfully detecting the anti-tumour drug paclitaxel in ovarian cancer 
biopsies and the antipsychotic drug spiperone in incubated rat liver. Reyzer et al. 
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followed several years later with the first example of MALDI-MSI, reporting the 
distribution of 2 orally dosed anti-tumour drugs in rat brain sections160 using targeted 
MS/MS on a triple quadrupole mass spectrometer. Early work in industry centered 
upon validation of the MALDI-MSI technique against labelled whole body analysis to 
establish the method as a viable unlabelled alternative or to complement qWBA 
data125,161. Khatib-Shahidi et al. successfully analysed olanzapine from rat whole body 
tissue sections162, including the simultaneous elucidation of the distribution of several 
olanzapine metabolites. Tissue specific protein markers (m/z values) were used to 
highlight different histological features within both mouse and rat whole body sections 
and rat brain. A similar approach was used to highlight glioma tumour baring tissue in 
mouse brain, highlighting the potential MSI has within the field of pathology. Drug 
distribution from whole body tissue sections has subsequently been extensively 
reported for other medicines including β-peptide163, vinblastine164, terfenadine128, 
raclopride112,127 and reserpine165. 
MSI analysis of tissues (organs) dissected from animals post mortem has become 
much more popular than whole body tissue section analysis in the R&D industry, 
largely because of the costs related to sectioning whole animals and the logistical 
considerations involved in handling and analysing such large samples. The list of drug 
compounds studied and the diverse range of tissues that have been analysed using 
MSI is now extensive, a concise summary is shown in table 4. 
Table 4: Summary of drugs studied using MSI (Updated and adapted 
from165,166) 
Drug Met. Tissue Ionisation 
Method 
Detection 
Mode 
Mass 
Analyser 
Ref. 
3-Methoxysalicylamine N Kidney, liver (mouse) MALDI MS/MS LTQ 166 
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Amphetamine, sibutramine 
& fluvoxamine 
Y Brain (rat) DESI MS, MS/MS Orbitrap 15 
Astemizole N Brain (rat) MALDI MS, MS/MS QqToF 167 
AQ4N Y Tumour (mouse) MALDI MS QqToF 168 
AZD2811 Y Tumour (mouse) DESI MS LTQ 
Orbitrap 
169 
AZD2820 Y Kidney (mouse) MALDI MS ToF/ToF, 
FTICR 
155 
AZD4017 N Brain (rat) LESA SRM QqQ 170 
AZD8329 N Brain (rat) LESA SRM QqQ 170 
AZx N Brain (rat) MALDI, 
LESA 
MS, SRM QqToF, 
SRM 
170 
BMS-X-P Y Liver, heart, lung, 
spleen (rat) 
MALDI MS/MS LTQ 171 
Brimonidine N Eye (rabbit) MALDI MS ToF/ToF 172 
Chlorisondamine N Brain (rat) MALDI MS, MS/MS ToF/ToF 123 
Chloroquine N Eye (Rat), whole 
body (rat) 
MALDI, 
LESA 
MS/MS, 
SRM 
QqToF, 
QqQ 
173,174 
Cimetidine N Lung (rat) MALDI MS ToF/ToF 77 
Clozapine Y Brain (rat), Lung, 
kidney, testis (rat) 
MALDI, 
DESI, LESA 
MS, 
MS/MS, 
SRM 
ToF/ToF, 
QqToF, 
LTQ 
6,111,12
5,175 
Cobimetinib N Brain (mouse) MALDI MS FTICR 176 
Cocaine N Brain (rat), Hair 
(human) 
MALDI MS, 
MS/MS, 
SRM 
ToF/ToF, 
QqQ 
123,177 
Dexamethazone N Eye (ovine)  MS ToF 178 
Ephedrine N Lung (rat) MALDI MS ToF 179 
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Erlotinib Y Liver, spleen, muscle 
(rat), tumour (human) 
MALDI, 
DESI, LESA 
MS, 
MS/MS, 
SRM 
QqToF, 
LTQ 
Orbitrap 
180,181 
Fosdevirine Y Brain (rabbit, guinea 
pig, monkey) 
MALDI MS FTICR 182 
Gefitinib N Tumour (human) MALDI MS, MS/MS LTQ 
Orbitrap 
181 
Gentamycin N Kidney (mouse) MALDI MS ToF/ToF 149 
Glucocorticoid receptor 
agonists 
N Skin (porcine) MALDI MS/MS ToF/ToF 183 
Haloperidol N Brain (rat) DESI, LESA MS, SRM LTQ 
Orbitrap 
6 
Ifosfamide & imatinib N Kidney (mouse) MALDI MS LTQ 
Orbitrap 
184 
Imipramine N Lung (rat) MALDI MS ToF/ToF 77 
Ipratropium N Lung (human) MALDI MS, MS/MS LTQ 
Orbitrap 
185 
Isoniazid N Lung (rabbit) MALDI MS/MS LTQ 84 
Ketoconazole N Skin (porcine) MALDI MS QqToF 186 
lapatinib Y Liver (dog) MALDI MS FTICR 187 
Lidocaine Y Skin (pig) DESI MS, MS/MS LTQ 
Orbitrap 
188 
Loperamide N Brain (mouse) MALDI MS/MS QqToF 189 
Midazolam N Brain (rat) LESA SRM QqQ 6 
MK-0916 N Brain (rat) MALDI, 
LESA 
MS, SRM QqToF 170 
Moxifloxacin N Lung (rabbit), liver, 
brain (rat) 
MALDI, 
DESI, LESA 
MS, SRM QqQ 6,32 
Nelfinavir N Cells MALDI MS ToF/ToF 190 
59 
 
Octreotide N Liver, kidney MALDI MS LTQ 
Orbitrap 
118 
Olanzapine Y Whole body, liver 
(rat) 
MALDI, 
DESI, LESA 
MS, SRM QqToF 17,162,1
91 
Oxaliplatin Y Kidney (rat) MALDI MS ToF/ToF 192 
Paclitaxel N Liver, tumour (rat) MALDI MS/MS Ion Trap 126,159 
Pictilisib & GNE-317 N Brain (mouse) MALDI MS FTICR 193 
Pirfenidone Y Lung, kidney, liver 
(mouse) 
MALDI MS FTICR 194 
Polymyxin antibiotics Y Kidney (rat) MALDI MS, MS/MS ToF/ToF 195 
Promethazine N Brain (mouse) MALDI MS/MS LTQ 
Orbitrap 
196 
Propranolol N Whole body (mouse) MALDI, 
DESI 
MS, SRM QqQ 153 
Raclopride N Whole body (mouse), 
brain, kidney (rat) 
MALDI MS/MS LTQ, 
ToF/ToF 
112,197 
Reserpine N Whole body (rat) MALDI MS LTQ 
Orbitrap 
165 
Rifampicin N Liver (rabbit) MALDI MS/MS LTQ 
Orbitrap 
119 
S-777469 N Whole body (mouse) MALDI MS LTQ 
Orbitrap 
127 
Saquinavir N Cells MALDI MS ToF, 
FTICR 
190 
SCH226374 N Brain (mouse) MALDI SRM QqToF 160 
SCH23390 N Brain (mouse, rat) MALDI, 
LESA 
SRM ToF/ToF, 
QqToF 
FTICR 
112,170 
Sparfloxacin N Skin (mouse) MALDI MRM QqQ 198 
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SR180711 N Kidney (rat) MALDI MS, MS/MS ToF/ToF 160 
Terfenadine Y Whole body (rat, 
mouse), liver (rat) 
MALDI, 
DESI, LESA 
MS, SRM QqToF 6,128 
Tiotropium N Lung (rat, guinea pig) MALDI MS, MS/MS ToF/ToF, 
LTQ 
Orbitrap 
115,199,
200 
Valiparib N Tumour (mouse) MALDI MS LTQ 
Orbitrap 
201 
Vinblastine N Whole body (rat) MALDI IM-MS/MS QqToF 164 
β-peptide N Whole body (mouse), 
tumour (human) 
MALDI MS ToF/ToF 163 
 
Drug distribution elucidated by MALDI-MSI has been the most heavily reported MSI 
technique over the past decade with recent publications in various research areas. 
Bartelink et al. reported the analysis of the oncology drugs valiparib and carboplatin 
within tumours by MALDI-MSI and ICP-MS (non-imaging). Concluding that the 
heterogeneous distribution observed could lead to insufficient drug exposure to ensure 
efficacy in select cell populations201. Complementary techniques such as DESI and 
LESA-MSI are beginning to become more highly reported, notably Shariatgorji et al. 
recently reported some interesting results using DESI-MSI to image several different 
neurotransmitters and neuroactive drugs using chemical derivatisation to charge tag 
amine groups within the molecules to increase sensitivity and detection15. 
MSI is increasingly being used to assess efficacy biomarkers after treatment with novel 
pharmaceuticals. Atkinson et al. described the distribution of the oncology drug AQ4N 
with its active metabolite in solid tumour168. Drug and metabolite distribution were 
simultaneously related to the intratumoral distribution of ATP indicating that the 
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cytotoxic metabolite was not confined to the hypoxic tumour regions. More recently, 
Ait-Belkacem et al. have characterised endogenous metabolism of transfected murine 
tumour models expressing various levels of indoleamine-2,3-dioxygenase1 (IDO1)202. 
ID01 is a potential therapeutic target for cancer treatment, IDO1 inhibitors are being 
developed to stimulate antitumour immuno-oncology responses. MSI is used here, to 
evaluate the conversion rate of IDO1, a tryptophan-degrading enzyme, by following 
both tryptophan and kynurenine relative abundances within two tumour models (high 
and low expression). The over-expression of IDO1 in tumour induces tryptophan 
depletion and increased levels of kynurenine, the opposite was observed in the IDO1 
low-expression model. These changes in the metabolites can affect the tissue at the 
cellular level by inhibiting NK and effector T-cell functions, activating regulatory T-cell 
phenotypes and M2-macrophages, generating tolerogenic dendritic cells. Thus, the 
kynurenine to tryptophan ratio was used as an indicator of IDO1 modulation and was 
linked to drug efficacy. Furthermore, a regional distribution of these metabolites 
throughout the tumour was used to describe different histological tissue (necrotic core, 
stroma or hypoxic tissues) by MSI. Finally, strong kynurenine accumulation and lower 
tryptophan levels were found to co-localise with IDO1 over-expression based on 
immunostaining showing a strong conversion rate of tryptophan. These local 
metabolite modulations were spatially correlated with drug distribution to explain 
mechanism of action and provide target engagement information. 
 
1.9.2 Drug metabolism 
The multiplex nature of MSI lends itself well to the analysis of both drug and metabolite 
distribution directly from the surface of tissue sections. Chen et al. reported the 
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analysis of terfenadine and its primary metabolite fexofenadine from mouse and rat 
whole body sections using MALDI-MSI128. This data was used to attribute the poor 
oral bioavailability of terfenadine to high first pass metabolism in the intestines and the 
liver prior to the drug reaching the systemic circulation. Similarly Goodwin et al. 
reported distribution data for drug candidate AZD2820 in mouse kidney using the 
multiplex nature of MALDI-MSI to show the distribution of a primary metabolite and 
highlight the screening power of MSI over conventional drug distribution techniques, 
in this case qWBA where the labelled nature of the analysis gave misleading 
representation of the AZD2820 distribution due to the presence of the radiolabel in the 
metabolite155. 
 
1.9.3 Toxicity studies 
To date most MSI studies within the pharmaceutical industry have revolved around 
questions of efficacy, largely through drug and metabolite distribution data. The 
technique is however being increasingly used in toxicology studies where it is regularly 
included into study plans to assess things like blood brain barrier penetration, where 
brain exposure may be suspected to yield a toxic response. It is also being used in 
post study assessment to answer pathology driven hypotheses, for example, when 
pathological findings have suggested a toxicological response in tissue MSI can be 
used to highlight a co-localisation of drug or metabolite in the affected area. 
Meistermann et al. used MALDI-MSI to investigate potential biomarkers of 
nephrotoxicity after administration of gemcitabine, a known nephrotoxicant to rats149. 
A spectral feature at 12,959 Da that strongly correlated with histopathology deduced 
alterations of the rat kidneys. The researchers were able to identify this spectral 
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feature as transthyretin (Ser(28)-Gln(146)) using other methods, demonstrating the 
emerging role of MSI in the discovery of toxicity biomarkers and in obtaining 
mechanistic insights concerning toxicity mechanisms. 
Nilsson et al. published a paper assessing the nephrotoxicity of polymyxin antibiotics, 
highlighting the correlation between the toxicity of different polymyxin analogues and 
the degree of accumulation of such drugs in the renal cortex of rats compared to the 
medulla195. This gave valuable insight into the potential ways new, less toxic 
analogues could be designed to combat the growing need for new antibiotics caused 
by increasing antibiotic resistance. 
Castellino et al. reported a study on fosdeverin, a HIV reverse transcriptase inhibitor 
that had shown adverse events in the clinic with 4 patients experiencing seizures after 
four weeks of treatment182. MSI was used to look into drug and metabolite distribution 
in rabbit, minipig and monkey brains highlighting inter-species variations in drug and 
metabolite distribution between humans, rabbit and minipig (which had high levels of 
a cysteine conjugate metabolite associated with the white matter of the brain) and in 
monkeys where the principle compound in brain was fosdeverin and this was 
associated mainly with grey brain matter. The authors were able to suggest several 
hypotheses for these different and novel distribution differences. 
Drexler et al. published details of a pathology driven toxicity study looking at the 
appearance of a birefringent microcrystalline material that had been observed in 
formalin fixed rat tissue sections171. MSI was used to show that the composition of the 
crystals was made up of the active drug substance (after the administration of a pro-
drug), MSI results were cross validated using several complementary techniques. 
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1.9.4 Drug delivery studies 
Drug delivery is becoming an important consideration in the hunt for new medicines. 
Elegant drug delivery methods can be used to prolong exposure and smooth out so 
called Cmax effects that can raise compound levels to potentially toxic levels, thus 
mitigating potential toxicity. Kreye et al. published a study using MSI to assess the 
release of theophylline and propranolol from slow release depot implants. MSI was 
used to show the temporal change in the structure of the implants and the release of 
the drugs into the external medium203. 
Zecchi et al. reported on the use of MALDI-MSI for the characterisation of two different 
routes of pulmonary drug administration of the anticholinergic drug tiotropium 
bromide200. The study found that the distribution of the drug in the lungs of guinea pigs 
varied considerably when administered by nebulised inhalation compared to 
intratracheal instillation at doses that induced significant anti-bronchoconstrictive 
activity. 
The use of nanoparticles is becoming increasingly popular, particularly within the area 
of oncology. The nanoparticles usually consist of larger molecules, delivery vesicles 
or particles that surround or incorporate drug molecules and capitalise on the 
hypothesis that the larger particles can access ‘leaky’ tumour vasculature and 
subsequently tumour tissue but are restricted from entering normally vascularised 
tissue. Once inside the tumour the larger particles find it difficult to get out and be 
cleared due to compromised lymphatic drainage, a phenomenon known as the 
enhanced permeability and retention effect (EPR). Ashton et al. reported use of a 
‘accurin’ based nanoparticle for the administration of AZD2811169. The accurin is made 
up of a polylactic acid/polyethylene glycol polymer which physically encapsulates the 
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drug molecules and a inert counter ion. Controlled release of the drug from the 
nanoparticle can be made faster or slower by using different counter ions. MALDI and 
DESI-MSI was used to map the distribution of the drug, a primary metabolite and a 
marker for the nanoparticle (L-poly lysine) in mouse tumour sections. Prolonged intra-
tumoural exposure was shown with the drug being largely undetectable in the tissue 
at 24 hrs after a single IV administration, compared to high exposure at 6 days post 
accurin administration at the same dose level. Clinical translation of the EPR effect is 
the subject of on-going research but it is an area where MSI could have some 
significant impact due to its ability to acquire multiple molecular species in each mass 
spectrum and monitor drug abundance, released drug and any possible nanoparticle 
accumulation within the tumours. 
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1.9.5 Target engagement 
Drug target engagement in cells or tissues is a key indicator of efficacy during drug 
development. Established techniques rely heavily on complex processing steps 
requiring many different reagents. MSI offers a label and reagent free method of 
monitoring target engagement in situ. Munteanu et al. reported a direct, quantitative 
approach using MALDI-MSI for measuring posttranslational modifications in cancer 
cells caused by histone deacetylase inhibitors in solid tumours204. The research 
showed a time-dependant decrease of nonacetylated histone H4 and a concomitant 
increase in acetylated H4 after administration of LBH-589 effectively monitoring drug 
induced mass shifts in protein ion intensities to quantify target engagement. 
 
1.9.6 Clinical translation and emerging applications 
 To date most MSI analysis has been performed on tissues from preclinical models. 
However, for a compound to effectively transition to humans and become a new 
medicine requires clinical research. Late stage failures are what can make or break a 
company so as much translational data as possible can be of significant benefit. MS 
based tools are being developed for surgery, providing molecular information directly 
from the cut tissue (REIMS and iKnife)205. To perform MSI analysis from clinical trials 
will need analysis needle or punch biopsies, such small samples can now be analysed 
by high resolution imaging platforms. 
The pharmaceutical industry is under increasing pressure to reduce the amount of 
animal experiments it performs during R&D and to have preclinical models that are 
more patient relevant. Advances in sample preparation techniques, instrument 
sensitivity and spatial resolution have enabled MSI to be applied to the analysis of 3D 
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and microphysiological systems (MPS). They are increasingly being employed within 
early drug discovery for efficacy and toxicity screening. Liu et al. reported on the 
application of MSI to a time dependant study of irinotecan in spheroids, showing for 
every treatment duration, an MSI image of the drug distribution several serial sections 
120 µm apart206. Harvey et al. reported on the use of MALDI-MSI for the analysis of a 
3D tissue engineered psoriatic skin model. MSI was used to to observe the spatial 
location of acetretin in ‘Labskin™’ living tissue equivalents, with the result that after 24 
hours, the drug was located in the epidermis of psoriatic and nonpsoriatic skin models, 
but after 48 hours of treatment, it was detectable in the dermis207.  
 
1.10 Future perspectives 
MSI has gained acceptance as an established tool within pharmaceutical R&D for the 
analysis of complex biological tissue samples. The multiplex nature of the technique 
makes it ideal for the simultaneous analysis of drug and metabolites in situ without the 
need for radio-labelled compounds that are needed in other, more traditional 
distribution studies. The combination of drug distribution images with endogenous 
lipid, peptide and protein detection makes the technique ideal for monitoring dose 
related changes in efficacy at the site of action or toxicity and can elucidate disease 
state progression. Advances in sample pre-treatment protocols, quantitative 
methodology and instrument hardware have created a suite of complementary, robust 
imaging techniques that can be used to explore various concepts within the drug 
discovery pipeline from early discovery through to the clinic. 
There is however still progress to be made, in the areas of spatial resolution, where, 
as drug development targets and new modalities become more complex, the need to 
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move to nano-scale imaging in single cells will become an increasing requirement. 
Instrument sensitivity and speed also need to be developed to accommodate this new 
spatial paradigm and achieve real high throughput analysis.  
Sample preparation techniques require further development to keep pace with the 
increased need for high throughput and address concerns over molecular post-
mortem tissue degradation and its subsequent effect on the ionisation profile of 
analytes. For MALDI the identification of new matrices that cover a wider chemical 
scope and the development of on-tissue derivatisation techniques is another area of 
future expansion that should ease the burden away from instrument developers and 
improve the sensitivity of existing platforms and increase the application of MSI to ever 
wider areas of pharmaceutical research. Robust sample preparation protocols that can 
be applied in multiple R&D laboratories are needed to achieve the metrology and 
standards that will allow MSI data to be accepted in regulatory submissions. This work 
is being undertaken at various national measurement institutions across the world and 
progress in this area is essential as MSI moves to the clinic, where large multisite 
studies are performed as a matter of routine. 
Higher throughput, higher spatial resolution and a subtle move towards increased use 
of 3D imaging bring problems of data storage. File sizes of 100GB+ are not 
uncommon, presenting researchers with data handling and backup issues that will 
need to be addressed by data reduction algorithms. Integration of MSI with multi modal 
high content imaging is an area that whilst being of benefit to the R&D business, could 
compound these data storage problems. Developments in artificial intelligence and 
machine learning will help to decrease this ‘big’ data burden, but these approaches 
are just beginning to emerge and are not yet widely adopted. 
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It is clear that MSI is a useful and important tissue imaging tool within pharmaceutical 
R&D. The technique has already made some impact in bringing new medicines to 
patients and looks set to build on this success and encompass even more areas of 
drug discovery for years to come. 
 
2.0 AIMS AND OBJECTIVES OF THIS PROJECT 
 
The aim of this project was to explore the use of mass spectrometry techniques to 
assess the biodistribution of drugs in tissues. To achieve this aim it was necessary to 
use and develop existing and emerging mass spectrometry imaging techniques and 
apply this state of the art technology to pharmaceutical R&D applications. The 
following objectives were investigated: 
• Evaluate different surface sampling MS ionisation interfaces and assess 
advantages and disadvantages when applied to the analysis of drugs in 
pharmaceutical R&D.  
• Apply MSI techniques to drug discovery projects to provide spatially resolved 
distribution information in early pharmacokinetic studies. 
• Assess the advantages of spatially resolved analytical methodology against 
traditional ‘gold standard’ bioanalytical methods used to determine drug blood 
brain barrier penetration. 
• Explore and develop the use of quantitative LESA-MSI, compare and contrast 
with other imaging platforms and traditional bioanalytical tissue analysis 
methodology. 
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• Apply quantitative MSI methods to drug discovery studies and aide 
development of robust pharmacokinetic/pharmacodynamic relationships based 
on target tissue concentration data.
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3.0 MASS SPECTROMETRY IMAGING OF CASSETTE-DOSED DRUGS FOR 
HIGHER THROUGHPUT PHARMACOKINETIC AND BIODISTRIBUTION 
ANALYSIS 
 
  
Swales, J. G.; Tucker, J. W.; Strittmatter, N.; Nilsson, A.; Cobice, D.; Clench, M. 
R.; Mackay, C. L.; Andren, P. E.; Takats, Z.; Webborn, P. J.; Goodwin, R. J., Mass 
spectrometry imaging of cassette-dosed drugs for higher throughput 
pharmacokinetic and biodistribution analysis. Analytical Chemistry 2014, 86 
(16), 8473-80. 
Reprinted with permission from Analytical Chemistry. Copyright 2014 American 
Chemical Society 
 
Author Contribution 
JGS designed the cassette dosed studies, aided necropsy, performed all sample 
preparation and LESA and MALDI imaging experiments (with the exception of 
high spectral and spatial resolution imaging), interpreted results and prepared 
the manuscript for publication. 
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4.0 MAPPING DRUG DISTRIBUTION IN BRAIN TISSUE USING LIQUID 
EXTRACTION SURFACE ANALYSIS MASS SPECTROMETRY IMAGING 
 
 
Swales, J. G.; Tucker, J. W.; Spreadborough, M. J.; Iverson, S. L.; Clench, M. R.; 
Webborn, P. J.; Goodwin, R. J., Mapping drug distribution in brain tissue using 
liquid extraction surface analysis mass spectrometry imaging. Analytical 
Chemistry 2015, 87 (19), 10146-52. 
 
Reprinted with permission from Analytical Chemistry. Copyright 2015 American 
Chemical Society 
 
Author Contribution 
JGS designed the blood brain barrier studies, aided necropsy, performed all 
sample preparation and LESA and MALDI imaging experiments, processed 
imaging data, interpreted results and prepared the manuscript for publication. 
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5.0 SPATIAL QUANTITATION OF DRUGS IN TISSUES USING LIQUID 
EXTRACTION SURFACE ANALYSIS MASS SPECTROMETRY IMAGING 
 
 
Swales, J. G.; Strittmatter, N.; Tucker, J. W.; Clench, M. R.; Webborn, P. J.; 
Goodwin, R. J., Spatial quantitation of drugs in tissues using liquid extraction 
surface analysis mass spectrometry Imaging. Scientific reports 2016, 6, 37648. 
 
Reprinted by permission from Macmillan Publishers Ltd. Copyright 2016 Nature 
Publishing 
 
Author Contribution 
JGS designed the quantitation studies, aided necropsy, performed all method 
development and proof of concept, sample preparation, performed all LESA and 
DESI qMSI imaging experiments, performed all homogenisation analysis, 
processed all data, interpreted results and prepared the manuscript for 
publication. 
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6.0 QUANTITATION OF ENDOGENOUS METABOLITES IN MOUSE TUMORS 
USING MASS SPECTROMETRY IMAGING 
  
Swales J. G., Dexter A., Hamm G., Nilsson A., Strittmatter N., Michopoulos F. N., 
Hardy C., Morentin-Gutierrez P., Mellor M., Andren P. E., Clench M. R., Bunch J., 
Critchlow S., Goodwin R. J. A., Quantitation of endogenous metabolites in mouse 
tumors using mass spectrometry imaging; Analytical Chemistry 2018, 90, 6051-
6058. 
Reprinted with permission from Analytical Chemistry. Copyright 2018 American Chemical 
Society 
 
Author Contribution 
JGS performed all method development and proof of concept experiments, 
designed and analysed the stability studies, performed all sample preparation 
and lactate MALDI imaging experiments, processed all imaging data, interpreted 
results and prepared the manuscript for publication. 
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7.0 SUMMARY AND CONCLUSIONS 
 
Mass spectrometry techniques have revolutionised pharmaceutical R&D. The industry 
has faced ever increasing pressure to develop and market drugs faster and with less 
attrition. To address this increased throughput a specific, sensitive, robust and 
versatile analytical technique was needed to keep up with the move to early, parallel 
elucidation of physiochemical and pharmacokinetic properties. By developing mass 
spectrometry based techniques for bioanalysis researchers were able to streamline 
sample preparation protocols capitalise on the multiplexed mass detection in order to 
simultaneously analyse several different analytes all in the same sample. This had a 
profound effect on how scientists conducted both in vitro and in vivo studies. 
 
7.1 Cassette dosing and analysis (Chapter 3) 
The ability of mass spectrometry techniques to analyse multiple compounds in a single 
analysis was a new paradigm in bioanalysis which in turn, allowed scientists to re-
evaluate how they conducted animal studies. For the first time researchers could 
simultaneous dose several compounds to animals all at the same time, typically called 
cassette dosing (or N-in-one dosing). The technique quickly gained widespread use 
for the elucidation of both oral and intravenous pharmacokinetic parameters of new 
chemical entities. These high throughput bioanalytical techniques gave quick and 
robust information about compound bioavailability and residence time within the body, 
enabling drug discovery projects to rapidly adapt design, make, test cycles to optimise 
potential new drugs, but did not address the question of drug distribution or indeed, 
reveal any localisation of a drug or its metabolites in the bodies major organs.  
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Mass spectrometry imaging had the potential to address these short comings and 
provide spatially resolved distribution data directly from these high throughput cassette 
dosed studies. As part of this thesis a study was undertaken to assess the impact MSI 
could have on cassette dosed studies. Hans Wistar rats were dosed either orally (PO) 
or intravenously (IV) with a cassette containing 4 non-proprietary pharmaceutical 
compounds or discretely with a representative compound from the cassette. Tissue 
samples were taken at 15 mins post dose for intravenously dosed animals or 2 and 6 
hrs post dose for orally dosed animals.  
 
7.1.1 MSI of cassette dosed drugs – Intravenous administration 
MALDI, DESI and LESA-MSI were used to assess the distribution of midazolam, 
bufuralol, clozapine and haloperidol in rat brain tissue sections after intravenous 
administration at 2 mg/kg/compound. The results from each platform are compared in 
chapter 3, figure 1. MALDI-MSI was initially used to analyse the samples, this 
technique successfully mapped the distribution of clozapine in brain but failed to detect 
the three other compounds in the cassette, despite experimentation with different 
MALDI matrices and solvent systems. DESI-MSI had more success, managing to 
detect bufuralol, clozapine and haloperidol and map the distribution of each compound 
in the brain tissue sections. Midazolam was detected in the brain sections but was of 
relatively low abunadance and it was not detected with sufficient mass accuracy to 
confirm identity. It was speculated that the limited positive detection rate of MALDI and 
DESI-MSI could be due to a variety of different reasons such as ion suppression or 
inherent low sensitivity of the MSI platforms to detect the compounds at the levels 
dosed and at the spatial resolution acquired (100 and 150 µm for MALDI and DESI 
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respectively) in the analysis. LESA-MSI, acquired at much lower spatial resolution, 
was successfully used to detect all of the four cassette dosed compounds in the brain 
tissue. The distribution profile of each drug was similar with all compounds showing 
relatively high abundance in the frontal cortex with little distribution into the rear left 
and right hemishperes of the cerebrum. The higher detection rate for LESA-MSI was 
attributed to the fundamentals of the technique, namely, wide chemical applicability 
due to the interface being based upon classical ESI, Increased sensitivity based on 
the lower spatial resolution and higher sampling area and the combination of the 
technique with a highly sensitive triple quadrupole mass spectrometer operating in low 
signal to noise ratio selected reaction monitoring mode. 
 
7.1.2 MSI of cassette dosed drugs – Oral administration 
A larger and more comprehensive study was designed to compare cassette dosing to 
discrete dosing after oral administration. Moxifloxacin, olanzapine, erlotinib and 
terfenadine were cassette dosed to Hans Wistar rats at 25, 10, 10 and 25 mg/kg 
respectively. In addition to the cassette dosing some animals were discretely dosed 
with either 25 mg/kg moxifloxacin or 10 mg/kg olanzapine. Plasma analysis by LC-
MS/MS revealed that all of the animals were successfully exposed to the drugs and 
that plasma concentrations of moxifloxacin and olanzapine were comparable between 
the cassette and discretely dosed animals indicating that dosing in a cassette was 
valid and had not caused any drug-drug interactions resulting in differences in 
exposure. 
Kidney sections were analysed using MALDI-MSI (chapter 3, figure 2). The detection 
rate for this analysis was 100% with all compound distributions being mapped at both 
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2 h and 6 h post dose for cassette and discretely dosed samples. All compounds 
showed a marked reduction in relative abundance between the 2 h and 6 h time point 
in the range 3-30 fold. This was reflected in the decrease in concentrations observed 
in the LC-MS/MS plasma analysis. Erlotinib and terfenadine were distributed in both 
the cortex and medulla of the kidneys whereas moxifloxacin and olanzapine were 
more localised in the medullary region. Consistent results between the discretely 
dosed moxifloxacin and olanzapine and the cassette dosed counterparts provided 
validation of the cassette dosing approach. 
Adjacent sections to those analysed by MALDI-MSI were subsequently analysed using 
LESA-MSI (chapter 3, figure 3). This analysis was done to provide some validation of 
the MALDI-MSI results by a complementary imaging technique and further 
substantiate the use of cassette dosing and MSI as a viable drug distribution tool in 
pharmacokinetic studies. Results from LESA-MSI correlated with those generated in 
the MALDI-MSI analysis showing a clear difference between the relative abundance 
of the analytes at 6 h compared to 2 h and good reproducibility of the distribution 
between the discrete and cassette dosed compounds. 
 
7.1.3 High Spectral and high spatial resolution MSI 
The versatility of the MALDI-MSI was further explored using high spectral and high 
spatial resolution mass spectrometry imaging. Lung tissue sections were analysed 
from the oral study, the presence of the dosed analytes was confirmed by accurate 
mass and comparison with vehicle dosed control tissues. High spatial resolution 
MALDI-MSI was used on adjacent sections to exemplify the power of the technique. 
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Chapter 3, figure 4 shows the distribution of olanzapine in the lung tissue overlaid with 
the distribution of heme as a marker for the tissue vasculature. 
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7.2 Blood-brain barrier penetration studies (chapter 4) 
Blood brain barrier penetration of potential new drugs has typically been difficult to 
accurately measure. Standard methods involve LC-MS/MS analysis of whole brain 
homogenates which yields a concentration of the drug throughout the entire brain but 
does not account for any localisation of the compound into specific compartments. If 
localisation does occur, the concentration of the drug is effectively diluted by the areas 
of the tissue where no drug is present leading to misleading results. Homogenate data 
is hindered further by the high levels of vasculature within the brain, the blood vessels 
contain residual blood which in turn contains drug, leading to an over-estimation of the 
brain concentration. MSI techniques can potentially mitigate these factors due to the 
inherent spatial resolution of the analysis and the multiplex nature of the techniques, 
allowing simultaneous mapping of blood markers (heme) to differentiate between 
residual blood contamination and real penetration of the drug substance into tissue. 
Liu et al. reported MALDI-MSI methodology that spatially resolved a compounds 
distribution across brain sections and correlated endogenous heme relative 
abundance to separate drug penetration in parenchymal tissue for residual blood 
contamination208. LESA-MSI had been shown in chapter 3 to be a useful technique to 
map the distribution of drugs in tissue, here the method is applied to BBB penetration 
studies and compared with gold standard LC-MS/MS analysis. 
A study was designed to assess the BBB penetration of a set of non-proprietary drug 
compounds. The compounds were selected based on historical homogenisation data 
that suggested they were either brain penetrative (MK-0916 and SCH23390) or poorly 
penetrative (AZD4017 and AZD8329). The poorly penetrative compounds having a 
brain/plasma ratio of 0.01 and 0.02 respectively with corresponding brain 
concentrations of 0.07 and 0.1 µM that were attributed to residual blood contamination. 
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Compounds were dosed as cassettes containing a penetrative and poorly penetrative 
compound by either IV (SCH23390 and AZD8329) or PO (MK-0916 and AZD4017) 
administration. Animals were culled at either 30 min or 2 h post PO dose or 1 min and 
30 min post IV admistration. 
 
7.2.1 Assessing BBB penetration after oral administration 
MALDI-MSI analysis detected both SCH23390 and MK-0916 and revealed a temporal 
difference between the early and late timepoints that reflected the known 
pharmacokinetics of the compounds (Chapter 4, figure 1). SCH23390 signal intensity 
was relatively high in the 1 min brain sample but was indistinguishable from vehicle 
dosed tissue at the 30 min timepoint. AZD4017 and AZD8329 were undetected by 
MALDI-MSI, this posed a unique opportunity to highlight the increased sensitivity 
LESA-MSI could deliver in this type of analysis, furthermore, the spatial resolution of 
LESA-MSI could be demonstrated to have significant advantages over 
homogenisation techniques. 
LESA-MSI was performed on adjacent brain tissue sections to those analysed by 
MALDI-MSI. Mass spectrometry images of AZD4017 and MK-0916 can be seen in 
chapter 4, figure 2. MK-0916 distribution by LESA-MSI was comparable to the images 
generated by MALDI-MSI. LESA-MSI did however detect AZD4017, signal intensity of 
the compound was low but distinctly higher than the background response from 
vehicle dosed tissue. This confirmed the higher sensitivity of the technique over 
MALDI-MSI. Correlation of the AZD4017 signal intensity with the signal intensity of 
heme was good, suggesting the response could be attributed to residual blood 
contamination but examination of the images revealed that the compound had a low 
level homogeneous distribution throughout the brain tissue indicating it was brain 
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penetrative. This demonstrated the advantages of LESA-MSI over homogenisation 
techniques, which had classed AZD4017 as nonpenetrant and highlights the value 
spatially resolved analysis can have when assessing marginally BBB penetrative 
drugs. 
 
7.2.2 Assessing BBB penetration after intravenous dosing 
LESA-MSI successfully detected both SCH23390 and AZD8329 in brain tissue at both 
the 1 min and 30 min timepoints, again highlighting the higher sensitivity of the LESA-
MSI technique over MALDI-MSI analysis. SCH23390 distribution was comparable to 
that observed in the 1 min sample analysed by MALDI–MSI. SCH23390 signal 
intensity in the brain sections at 30 min post dose was higher than that observed in 
vehicle dosed tissue. AZD8329 was detected at low signal intensities in both the 1 min 
and 30 min brain sections, again this was significantly higher than the background 
response in control tissue. AZD8329 signal intensity was consistent across the 1 min 
and 30 min timepoints with both also showing a homogeneous distribution of the 
compound throughout the tissue indicating the compound is poorly penetrant. 
Correlation of the compound signal intensity against that observed from heme 
confirmed the homogeneous distribution and penetration of the compound into brain 
tissue at low levels, a result that was missed using homogenisation methods. 
  
115 
 
7.2.3 Application of LESA-MSI in drug project BBB penetration studies 
LESA-MSI was applied to the analysis of AZx, a compound being developed within 
the cardiovascular therapeutic area within AstraZeneca. The LESA-MSI analysis of rat 
brain tissue sections revealed that AZx was highly localised into various ‘hot spots’ 
throughout the tissue (chapter 3, figure 4). The signal intensity of AZx correlated well 
with heme indicating the response could be attributed to residual blood contamination. 
In addition the compound was not present in areas of the brain tissue which did not 
contain heme confirming the compound had very poor brain penetration. MALDI-MSI 
was used to analyse adjacent tissue sections confirming AZx co-location with heme, 
providing further validation of the LESA-MSI technique and indicating that LESA-MSI 
could be used to highlight localisation of drugs in tissues even at low (1000 µm) spatial 
resolution. 
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7.3 Quantitation of drugs in tissues using MSI (chapter 5) 
Quantitative MSI techniques have been widely reported and discussed earlier in this 
thesis (chapter 1.5). LESA-MSI had been shown in chapters 3 and 4 to be an effective 
tissue imaging technique, generating low spatial resolution qualitative images that had 
been validated against MALDI and DESI-MSI as other representative imaging 
techniques. The next logical step was to assess the suitability of LESA-MSI to perform 
quantitation experiments of drugs in tissues. 
A study was designed in Hans Wistar rats that dosed 1 animal with vehicle, 2 animals 
were dosed discretely with olanzapine (10 mg/kg) and 2 animals were dosed with a 
cassette of four compounds, moxifloxacin, olanzapine, erlotinib and terfenadine at 25, 
10, 10 and 25 mg/kg respectively. Liver samples were taken at necropsy at 2 and 6 
hrs post dose, post sectioning the amount of each drug in liver samples was quantified 
using LESA-MSI, DESI-MSI and by LC-MS/MS after homogenisation. 
 
7.3.1 Mimetic tissues 
LESA-MSI is a low resolution imaging method, typically creating images with a spatial 
resolution of 1000 µm pixel to pixel. The low spatial resolution of the technique 
rendered the qMSI ‘spotting’ technique unsuitable for use in this instance due to the 
limited size of the calibration spots, this would mean only a single extraction could be 
done at each calibration point. Instead, the tissue mimetic model was employed to 
provide homogenised tissue ‘spiked’ with the analytes at various calibration 
concentrations, these homogenates could then be frozen and sectioned to give tissue 
sections large enough to perform at least 10 extractions per calibration point. 
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7.3.2 Optimisation of LESA methods (Appendix II) 
In order to establish a reliable, robust quantitation method it was necessary to firstly 
optimise the LESA extraction method. The LESA extraction solvent, tissue thickness, 
solvent dwell time and the effect of using an internal standard in the analysis were all 
explored. Mimetic liver tissue standards were used as representative homogeneous 
tissues to perform the optimisation experiments. The mimetics were spiked with a 
cassette of four compounds (clozapine, albendazole, tamoxifen and astemizole) to 
cover a LogD range between 2.9 and 4.0. 
Optimisation of the extraction solution using isopropyl alcohol, methanol and 
acetonitrile was performed (appendix II, figure SI 1). Signal intensities of the extracted 
compounds varied significantly depending on which solvent was used in the solution 
and the proportion they were diluted with water. Acetonitrile mixed in a ratio of 60/40 
v/v with water was found to be the optimum solvent composition in terms of extraction 
efficiency, robustness and reproducibility. Tissue thickness was found to only 
negligibly effect the intensity of compounds extracted from the mimetic tissues 
standards (appendix II, figure SI 2), 12 µm was subsequently used to maintain 
consistency with other MSI methods. Solvent dwell time was found to be optimal at 3 
secs per extraction, shorter times resulting in lower signal intensities of drugs extracted 
and longer dwell times resulting in loss of the liquid micro-junction between the pipette 
tip and the tissue surface (appendix II, figure SI 3). The use of an internal standard 
(IS) either sprayed across the tissue (using a nubulising automated sprayer) or spiked 
directly into the extraction solvent was explored using both structurally similar and 
stable isotope-labelled versions of the analytes. The use of an IS sprayed over the 
tissue was shown to increase signal intensity variability using both the structurally 
similar compound and the stable isotope-labelled variant. Inclusion of the stable 
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labelled compound into the extraction solvent was found to improve variability 
(appendix II, SI table 1-3). 
 
7.3.3 Quantitation of study samples using LESA-MSI 
Rat liver sections taken from the vehicle, cassette and discretely dosed animals were 
analysed using LESA-MSI. Alongside these ‘unknown’ samples liver mimetics 
cassette spiked with different concentrations of each compound in the range 0 – 100 
nmol/g were analysed in the same analytical run. The analytes were found to be 
distributed continuously but at various abundances throughout the study samples 
(chapter 5, figure 1). Calibration curves derived from the mimetic liver tissues were 
found to be acceptable in terms of linearity and linear range for subsequent back 
calculation of the compounds in the ‘unknown’ samples. Accuracy of the measured 
concentration versus the nominal concentration of each calibration standard was also 
found to be within the limits normally accepted for bioanalysis (chapter 5, figure 2). 
These results indicated that LESA-MSI could be used as a viable quantitative 
technique for the measurement of drug concentrations in tissues. 
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7.3.4 Comparison of LESA-qMSI with tissue homogenisation 
and DESI-qMSI 
The mean intensity for each ‘unknown’ liver section was back calculated from the 
mimetic calibration curves for each compound giving a concentration value that could 
be directly compared to concentration values generated from the same sample of liver 
by homogenisation followed by analysis by LC-MS/MS. Adjacent tissue sections were 
also analysed using DESI-MSI, again, using the mimetic calibration standards 
alongside the ‘unknowns’. Correlation between the results generated by LESA-MSI 
and those generated by LC-MS/MS ranged from 3.8 – 35.1% difference across the 
different compounds and time-points. These values are considered to be within the 
variance expected when comparing different analytical techniques and provided some 
validation of the LESA-MSI quantitation against what is recognised as the gold 
standard for quantitative measurement. DESI-MSI quantitation was performed as a 
direct comparison of LESA-MSI with another imaging technique. DESI-MSI compared 
well with LESA-MSI showing (using DESI as the standard) between 0.8 – 44.4% 
difference across the different compounds and timepoints. This gives further validation 
of the use of LESA-MSI as a quantitative technique. DESI-MSI was also compared to 
the data generated using LC-MS/MS displaying a range of 5.4 – 41.2% difference for 
olanzapine, moxifloxacin, erlotinib and terfenadine. This was the first time quantitative 
DESI-MSI had been reported in comparison with data generated by alternative 
techniques. 
The data supported the use of LESA-MSI as a credible, quantitative technique for the 
measurement of drug concentrations in tissues, furthermore, it showed that the tissue 
mimetic model of calibration standard preparation worked across two different imaging 
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platforms, having already been used in MALDI-MSI analysis by Groseclose and 
Castellino116 indicating its applicability across multple modes of qMSI. 
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7.4 Quantitation of endogenous metabolites in tumour 
tissues using MSI (chapter 6) 
The research described in chapter 5 explored LESA and DESI-qMSI methodology and 
established the techniques as reliable quantitative methods to assess the 
concentration of drugs in tissues. The acquisition of drug concentrations in target 
tissues or at sites of toxicity is important information for researchers, allowing for 
example, evaluation of drug level coverage over an enzymatic IC50 in order to indicate 
the duration of effect or allowing calculation of toxicity dose margins. qMSI techniques 
have the potential not only monitor drug distribution and concentration but also monitor 
drug induced changes in endogenous molecule levels such as metabolites, lipids, 
proteins and peptides. Furthermore, insights into the distribution of these endogenous 
compounds could help with understanding the complex tissue architecture in diseases 
such as cancer. 
Cellular metabolism is often different between healthy tissue and cancer cells. Drug 
targets often inhibit metabolic pathways leading to up and down regulation of key 
metabolic markers. Chapter 6 focusses on using qMSI techniques to quantify 
endogenous metabolites involved in cellular metabolism. Lactate and glutamate are 
intrinsically involved in cellular energy production in processes such as glycolysis, 
glutaminolysis and Krebs cycle. Measurement of any drug induced changes in these 
metabolites within tumours would offer direct evidence of compound efficacy. 
Quantitation of these key changes, together with drug levels can then be used to build 
accurate and robust in-silico pharmacokinetic/pharmacodynamic models to evaluate 
the potential efficacy of new chemical entities and reduce the number of in vivo 
experiments and animals used to develop new medicines.  
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7.4.1 Stabilisation of endogenous amino acids in tissues 
In order to establish a reliable, robust quantitation platform it was necessary to ensure 
that any sample pre-treatment minimised any endogenous compound degradation 
within the tissues. An experiment was designed to evaluate the stability of four 
endogenous metabolites: lactate, glutamate, aspartate and glutamine, throughout the 
MSI pre-treatment workflow. Kidney sections were fixed and stored under different 
conditions over a 24 h period, either (1) left in the cryostat thaw-mounted at -16°C, (2) 
thaw-mounted, desiccated in N2, vacuum packed and stored at room temperature, or 
(3) thaw-mounted desiccated in N2, vacuum packed and stored at -80°C. Analysis was 
performed using DESI-MSI, a fresh kidney section was applied to each microscope 
slide directly prior to analysis to give a baseline abundance of the metabolites. Results 
can be seen in chapter 6, figure 1. Spectral clustering was used to define regions of 
interest for the cortex and medulla of each kidney and the mean relative abundance 
of the four amino acids in each region was extracted. The results indicated that kidneys 
treated and stored under conditions (3) showed far greater stability of the four 
metabolites in both the cortical and medullary regions of the kidney sections. Even 
with these protocols in place, degradation could still occur during the time taken to 
section multiple tissues onto the same microscope slide. To eliminate this risk multiple 
tissues were embedded in a suitable embedding media to allow the production of 
multiple tissue sections in a single cut of the cryostat blade, reducing the time the 
sections spend at temperatures less than -20°C and reducing sample preparation 
time. 
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7.4.2 Initial proof of principle for qMSI lactate quantitation 
A study was performed in a NCI-H358 human xenograft mouse tumour model (n=20 
animals). Animals were dosed with vehicle and euthanised at 0.5, 2, 6 and 24 h post 
dose to mimic a typical pharmacodynamic study design. Tumours were excised at 
necropsy, immediately snap frozen and stored at -80°C prior to sectioning. Tumours 
were sectioned using the protocols set out in section 7.4.1. MALDI-qMSI analysis 
applying spots of a stable isotope-labelled standard of lactate at different 
concentrations onto control tissue and forming a calibration line to back calculate 
lactate levels within the tumour sections from each animal at each time-point was 
carried out. The results from the analysis (chapter 6, figure 2) showed that the 
analytical method performed well. Due to the unavailability of a second, different 
stable-labelled version of lactate to perform pixel to pixel normalisation, the MSI data 
was normalised using total ion current. Further interpretation of the results revealed 
that the inter-tumour lactate levels in the tissue had a high level of variation. Lactate 
distribution was heterogeneous throughout the tissue sections and was present at 
higher concentration in areas of necrosis. Glutamate distribution was also extracted 
from the dataset. This was not part of the quantitative study but is of interest as another 
cellular metabolite involved in energy production. Glutamate distribution was much 
more homogeneous throughout the tissue sections compared with lactate. 
 
7.4.3 Screening different tumour models for lactate and glutamate 
concentration and heterogeneity 
The high concentration variability and heterogeneous distribution of lactate in the initial 
qMSI proof of principle study indicated that a tumour model that had lower variability 
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and a more homogeneous distribution of lactate may allow a more accurate 
assessment of the endogenous metabolite levels within the tumour tissues and make 
any modulation in later vehicle matched, drug dosed studies easier to detect. It was 
decided to screen four different tumour models. An NCI-H358 model, differentiated 
from the initial study by allowing the tumour to grow for less time and minimise the 
chance of necrosis, a MC38 model, a B16.F10.AP3 model and an MC38 variant model 
were all screened using MALDI-qMSI for both lactate and glutamate quantitation and 
distribution. Results of the analysis can be seen in chapter 6, figure 3a. Tumours from 
the MC38 and B16.F10.AP3 models showed heterogeneous lactate distribution 
throughout the tumour tissue with little or no co-localisation with glutamate. The MC38 
tissue in particular had large areas of necrosis, B16.F10.AP3 tumours were less 
necrotic but lactate and glutamate distribution was very localised and ‘patchy’ 
throughout the tissue. The NCI-H358 and MC38 variant tumours had more evenly 
distributed lactate and glutamate even in areas that were confirmed to be necrotic by 
H&E staining. 
Lactate and glutamate concentrations across each of the tissue sections were largely 
in the same range between the different models fluctuating between 81.7 – 2504.0 µM 
for lactate and 1095.5 – 7818.7 µM for glutamate. 
 
7.4.4 Region-specific quantitation of lactate and glutamate and assessment of 
heterogeneity 
Spectral clustering was performed on each of the individual tissue sections from each 
model. This analysis allowed region-specific pixel by pixel quantitation of the lactate 
and glutamate levels to be calculated, this is represented graphically in the box plots 
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in chapter 6, figure 4. From the box plots of lactate and glutamate concentration in 
each region of each tissue, the lactate concentration was much more heterogeneous 
in the B15.F10.AP3 and MC38 models as seen by the large boxes, whiskers and many 
outliers. In comparison, the MC38 variant and NCI-H358 tumours had a more 
homogeneously distributed lactate concentration (smaller boxes) with the MC38 
variant displaying lower median inter-tumour lactate concentration variability. The 
glutamate concentration in all tissue models was overall less heterogeneous than the 
lactate concentration, with the different models containing similar levels of 
heterogeneity as seen by similar spreads of the data in the box plots. 
The objective of the screening exercise was to identify a tumour model that had greater 
lactate homogeneity, lower lactate variability and fewer areas of necrosis. The MC38 
variant model was selected as the analysis had shown this exhibited the most 
favourable properties of the four models tested. Subsequently, the MC38 variant 
model has allowed further efficacy studies to be performed. This was highlighted in 
initial efficacy study data which showed inter-tumour lactate concentration (measured 
by LC-MS) in control tumours varied by ±22%. 
 
7.5 Final conclusions 
The aim of this thesis was to investigate the use of mass spectrometry methods for 
profiling drug distribution in biofluids and whole tissues. The work reported herein has 
shown that mass spectrometry imaging techniques have wide applicability in the field 
of drug research and development, providing valuable insight into drug distribution, 
quantitation and efficacy. The techniques discussed were validated against traditional 
‘gold standard’ LC-MS methods where appropriate. It is neither intended or expected 
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that MSI techniques will replace these tried and tested methods, but act in a 
complementary capacity when spatially resolved information is required to understand 
drug efficacy or toxicity. MSI is now being routinely applied to drug projects across the 
AstraZeneca development portfolio and within other large pharmaceutical 
development organisations. 
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